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CHAPTER ONE 
Introduction 
Pelvic floor dysfunction (PFD) encompasses a broad spectrum of neuromuscular 
disorders of the pelvic floor, resulting in a wide array of functional problems in women. 
Abnormal function of the pelvic floor musculature is a poorly understood entity and often 
described as the mechanical and neurological disruption of the normal functional 
anatomy of the pelvic floor (Butrick, 2009; Davis & Kumar, 2003; Finamore, 2008). It 
presents as low or high tone pelvic floor musculature and is often associated with 
symptoms of urinary and fecal incontinence, urinary urgency/frequency, voiding 
dysfunction, obstructed defecation, pelvic organ prolapse, sexual dysfunction and pelvic 
pain. It is thought to be a contributing factor in 70% of women who present with 
genitourinary, bowel, and sexual disorders (Wehbe, Whitmore, & Kellogg-Spadt, 2010). 
Frequently cited contributory factors include pregnancy, obstetrical trauma, multi-parity, 
estrogen deficiency in menopause, previous pelvic floor surgery, coexisting medical 
conditions (e.g. diabetes and congenital tissue disorders), neurological disorders 
impairing pelvic floor function, and obesity related disorders increasing abdominal 
pressure (Butrick, 2009; Davis & Kumar, 2003). 
It is becoming increasingly common to offer nonsurgical treatment to women 
with PFD. Nonoperative management may include a variety of therapies such as pelvic 
floor muscle training (PFMT), biofeedback, electrical or electrogalvanic stimulation 
(EGS), constipation management, behavior modification, incontinence devices, and 
pharmacotherapy including antimuscarinic medications and vaginal estrogen. There is no 
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generally accepted consensus for the correct approach to the nonoperative management 
of PFD, but a multifaceted approach is often used. A typical treatment plan includes 
several different therapeutic modalities that have been selected to provide the best chance 
of cure.  
There is a paucity of literature evaluating the aggregate clinical effect of 
comprehensive, multimodal nonsurgical pelvic floor rehabilitation. Current research is 
primarily focused on the use of physical therapy administered by a physical therapist or 
physiotherapist which includes but is not limited to PFMT and biofeedback to treat 
urinary and fecal incontinence (Barroso, Ramos, Martins-Costa, Sanches, & Muller, 
2004; Bendana et al., 2009; Dumoulin & Hay-Smith, 2010; Hay-Smith, Herderschee, 
Dumoulin, & Herbison, 2012; Norton & Cody, 2012; Rai, Cody, Alhasso, & Stewart, 
2012). The improvement in symptoms afforded by mono modal PFMT is modest, with 
approximately 43% reported improvement in outpatient non-group therapy (Hay-Smith et 
al., 2012).  
 A retrospective analysis of 728 women who underwent five sessions of pelvic 
floor rehabilitation with an advanced practice nurse (APRN) in an outpatient academic 
urogynecology clinic revealed a mean improvement of 80-85% in urinary, defecatory and 
pelvic pain complaints (Starr et al., 2013). These outcomes are significant, but what the 
researcher failed to do was to follow these women over time. Several questions remain 
unanswered including: 1) “How effective is comprehensive management of PFD by an 
APRN over time?”  2) “If symptom control was maintained, what variables predicted 
symptom stability?”  There is a paucity of literature in the nonoperative treatment of 
women with PFD. The proposed study is an attempt to gain insight, into the complex 
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management of these conditions and make a scientific contribution to the literature for 
non-surgical management of women with these life-altering symptoms. 
Background and Significance 
PFD includes symptoms of urinary incontinence, pelvic organ prolapse, anal 
incontinence, sensory abnormalities of the lower urinary tract, defecatory dysfunction, 
pelvic pain and painful intercourse. Symptoms of PFD are not life threatening but can 
have a life altering effect on women. The fear of leaking urine or stool can lead to 
increasing anxiety and sometimes social isolation and depression (Bezerra et al., 2014). 
Some women are hesitant to exercise, travel or even engage in intimate relationships. 
Many consider these symptoms a normal part of aging, and believe the only available 
treatment is medication or surgery (Townsend, Matthews, Whitehead, & Grodstein, 
2013). This is just one of many reasons why incontinence symptoms often go unreported.  
In addition, women are often embarrassed to discuss incontinence and prolapse with their 
health care provider as these conditions can take a back seat to other more important 
health problems such as heart disease and diabetes. Symptoms of PFD are considered life 
altering, not life threatening and if the health care provider does not have adequate time 
to address them during a routine office visit, they often go undiagnosed and untreated.  
The prevalence and economic burden of PFD is high and continues to increase annually. 
Challenges exist in measuring the exact effect of these symptoms due to variability in 
definition and lack of symptom report by patients (Nygaard et al., 2008). 
Normal function of the pelvic floor musculature is a critical component in 
maintaining pelvic stability, pelvic organ support and normal function of the female 
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pelvic organs. Voluntary control of this muscle group is essential to allow for defecation, 
micturition, parturition, sexual function, urinary and fecal continence. High tone pelvic 
floor dysfunction (HTPFD) is a neuromuscular disorder of the pelvic floor that 
contributes to symptoms of PFD in women such as urinary and fecal incontinence, 
voiding dysfunction, constipation of obstructed defecation, sexual dysfunction and pain 
syndromes. HTPFD can lead to an inability to relax the pelvic floor muscles, often 
resulting in symptoms of PFD in women. Because HTPFD is often overlooked in clinical 
practice and because it contributes to costly conditions such as urinary incontinence, 
constipation and pelvic pain, it is important for the health care community to focus on 
heightening clinician awareness of the condition, standardizing pelvic floor terminology 
and pelvic muscle exam and educating providers about available treatments. Because a 
comprehensive review of the literature on symptoms associated with PFD would be 
overwhelming and because HTPFD is often goes unrecognized as a cause of PFD, the 
researcher chose to conduct a review of the literature on HTPFD, which is presented in 
manuscript form in chapter two. 
Establishing ambulatory rates for patient care associated with PFD is difficult, 
commonly relying on large national databases. It is estimated that future demands for 
incontinence and prolapse care will increase significantly based on ambulatory care 
projections. Estimates of direct costs of pelvic organ prolapse and stress urinary 
incontinence surgery exceed one billion dollars and costs for ambulatory care related to 
PFD in 2006 exceeded $410 million (Subak et al., 2001; Sung, Washington & Raker, 
2010).  
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Pelvic floor disorders often coexist and it is estimated that 23.7% of women have 
one or more pelvic floor disorders (Nygaard et al., 2008).  As the population ages, health 
care utilization for PFD is predicted to grow. Wu and colleagues (2010) used US Census 
Bureau population projections to estimate the total number of women who will undergo 
surgery for pelvic organ prolapse from 2010 to 2050 and determined that this number is 
expected to increase by 48.2% over these four decades. 
The limitation of studies on health care utilization is that some women with PFD 
do not seek care. In a population-based sample of women 40 years or older, the 
prevalence of UI was 41%; but only 25% of symptomatic women sought care, 23% 
received some care, and 12% received subspecialty care (Minassian et al., 2012).  In a 
community-based Internet survey of women older than 45 years, 19% reported accidental 
bowel leakage but only 29% of those had sought care (Brown, Wexner, & Lukacz, 
2013). Thus, the incidence of care seeking provides an underestimate of the public health 
burden of PFD among women in the United States. 
Traditional management of PFD in women has followed a clinically 
compartmentalized and fragmented approach, potentially failing to address 
multicompartmental symptomology resulting in incomplete resolution of the problem. 
Women with symptoms PFD often consult with many different health care providers, 
increasing the potential for duplication and delay in treatment. Multiple referrals can 
result in increased cost of care and decreased patient satisfaction. Because coexisting 
pelvic floor disorders are common, evaluation and management of all pelvic floor 
symptoms by a health care provider specializing in the treatment of PFD could improve 
overall outcomes for women.  APRNs in a urogynecology clinic are uniquely positioned 
 
 
6 
 
to provide comprehensive care to women with urinary, defecatory and pelvic pain 
complaints. Ongoing research is needed to advance the science of comprehensive 
nonsurgical management of symptoms of pelvic floor dysfunction by an APRN, resulting 
in improved QOL for women with these life altering symptoms.  
Prior Research 
  A retrospective review was conducted between 2009 and 2012 in an academic 
outpatient practice in Mid Missouri of 728 women who underwent comprehensive pelvic 
floor rehabilitation by an APRN. A conglomeration of PFMT, biofeedback, behavior 
modification, EGS, incontinence devices and various indicated pharmacotherapies 
revealed a mean symptom improvement of 80-85% in urinary, defecatory and pelvic pain 
symptoms (Starr et al., 2013). This is the largest PFD nonsurgical data set published to 
date. Treatment success was thought to be a result of APRNs providing the therapy as 
they are equipped to address a diversity of pelvic floor health needs that could not be 
immediately addressed by a physical therapist or physiologist who also provide 
outpatient care to women with symptoms of PFD. For example, the patients with 
urogenital atrophy were prescribed vaginal estrogen, patients with pelvic floor muscle 
spasm were prescribed muscle relaxants, and patients with pelvic organ prolapse were 
fitted with pessaries. Although anti-muscarinic medications could be prescribed, this was 
rarely required. Additionally, the APRNs were trained to administer PFMT with 
biofeedback, as well as intravaginal EGS. The ability to provide this level of care was a 
likely contributor to the overall success of therapy (Starr et al., 2013). 
 
 
7 
 
 However, scientifically it is difficult to determine why this program was such a 
success. One possibility is regular health professional contact, accountability, and 
oversight of the patients. In two recent Cochrane reviews of  the treatment of urinary 
incontinence, a pattern emerged in which women receiving more health professional 
contact were more likely to report improvement compared to women doing  with little or 
no supervision (Hay-Smith et al., 2012; Herderschee, Hay-Smith, Herbison, Roovers, & 
Heineman, 2011). It is unclear whether this improvement is related to the facilitation of 
patient compliance with various therapeutic modalities, placebo effect from the 
perception of higher quality care or a desire of patients to please their caregivers by 
reporting symptom improvement. Regardless of the mechanism, patient satisfaction 
scores reported for this service through a national patient satisfaction survey (Press-
Ganey) were consistently the highest in this academic system, often approaching 97% 
(Starr et al., 2013).  
The APRNs in this retrospective review gave each patient a clear expectation 
regarding potential outcome of treatment, taking into consideration their main 
complaints, physical examination findings, medical history, cognitive ability, and even 
financial and transportation options to achieve the best outcome. They addressed co-
morbidities and their effect on success such as morbid obesity, diabetes, smoking and 
age. Those with urinary, defecatory and pelvic pain symptoms and minimal co-
morbidities were told they had a chance of achieving at least 80% improvement with an 
average of five treatments if they were compliant with exercise and behavior 
modification. It is worth noting that the number of times patients performed home pelvic 
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muscle exercises correlated positively with reported percentage of symptom 
improvement (at least 4xday, p=0.005; at least 2xday. p=0.03) (Starr et al., 2013).  
Although these patients reported excellent clinical improvement in urinary, 
defecatory and pelvic pain complaints, this study has significant limitations and its 
findings must be interpreted cautiously. First, it was a retrospective study and is not 
generalizable due to several limitations including convenience sampling and lack of a 
comparison group. Only outcomes among subjects who presented for therapy and 
returned for multiple subsequent visits were analyzed. These individuals likely represent 
some of the most motivated patients in the population. Additionally, a subjective, non-
validated instrument was used to measure the primary outcome. “The patient was asked 
to report “percentage of symptom improvement” in urinary, defecatory and pelvic pain 
symptoms at each successive treatment session. While internal validity of this 
measurement is uncertain, this outcome instrument can be considered a form of global 
rating assessment, which, as a class, provides a robust and reproducible measure. 
Moreover, the large sample size decreased the impact of outliers on the results. Another 
limitation was lack of data collection of long-term symptom control. The patients 
reported significant improvement immediately following treatment but the long-term 
effects of treatment were not measured. 
Current Study  
A more scientific analysis of symptom outcomes and long-term effect of 
nonsurgical management of symptoms of PFD is needed to advance the science of PFD.  
With this in mind, this researcher designed a prospective database which was approved 
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by the University of Missouri Health Science IRB in 2013. All women who presented to 
this academic outpatient urogynecology practice for comprehensive pelvic floor 
rehabilitation by an APRN were asked to enroll. Validated questionnaires including the 
Pelvic Floor Distress Inventory-20 (PFDI-20) and Pelvic Floor Impact Questionnaire-7 
(PFIQ-7) were used to measure changes in QOL. Visual Analog Scales (VAS) were used 
to track subject perceived symptom improvement. The PFDI-20 and PFIQ-7 
questionnaires were completed at initiation and end of treatment and mailed to the 
subjects at six months and one year to determine long-term treatment effect on QOL. The 
subjects also completed the VAS at each successive treatment session, six and twelve 
months to track individual changes in urinary, defecatory and pelvic pain complaints. To 
date, 428 women have been enrolled.  The second manuscript, presented in chapter three 
is a secondary analysis of the data collected for this review.  
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CHAPTER TWO 
Manuscript: High Tone Pelvic Floor Muscle Dysfunction: A Review of the Literature 
Title 
High Tone Pelvic Floor Muscle Dysfunction: A Review 
Abstract 
High tone pelvic floor dysfunction (HTPFD) can be a contributing factor to pelvic 
floor dysfunction (PFD) and is often overlooked when assessing and treating women with 
pelvic floor symptoms. A comprehensive literature search was completed in October 
2016 and included specific key words such as pelvic floor dysfunction, pelvic pain, rectal 
pain, and dyspareunia. Literature from PubMed, CINAHL and MEDLINE databases 
published between 1900 and 2015 was searched for relevant research and information. 
The search strategy also included a manual review of all relevant articles for further 
references. Only search results with English language abstracts were reviewed. A total of 
256 potentially relevant studies were initially identified. After abstract review, 102 
manuscripts were recognized as pertinent. Following review of the manuscripts, 45 
articles and two systematic reviews were identified as pertinent. This manuscript will 
briefly review the anatomy, symptomology, associated conditions and physical 
evaluation of HTPFD in women with a more comprehensive review of the literature of 
the currently accepted treatment modalities. 
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Introduction 
High tone pelvic floor dysfunction (HTPFD) is a neuromuscular disorder of the 
pelvic floor that contributes to a variety of pathological conditions in women such as 
urinary and fecal incontinence, voiding dysfunction, constipation of obstructed 
defecation, sexual dysfunction and pain syndromes. The prevalence of the syndrome in 
the general population is estimated at 6.6%, and is thought to affect more than 10 million 
women in the United States alone. This disorder can present as pelvic pain, dyspareunia, 
rectal pain, chronic constipation, low back pain, vaginal and vulvar pain, urinary 
urgency/frequency, incontinence, hematuria and voiding dysfunction. As a result of the 
various presenting symptoms, women with HTPFD are seen by a variety of health care 
providers including primary care providers, obstetrician-gynecologists, urogynecologists, 
urologists, colorectal surgeons, orthopedic surgeons, chiropractors, pain management 
specialists, physical therapists, psychotherapists and others. Because the symptoms are 
vague, and the index for suspicion on the part of the health care provider is low, the 
diagnosis is frequently missed, and the patient is usually seen by several providers 
without relief. The purpose of this manuscript is to briefly discuss the anatomy, 
symptomology, associated conditions and physical evaluation of HTPFD in women with 
a more comprehensive review of the literature of the currently accepted treatment 
modalities. Heightened awareness of this condition can contribute to improved 
assessment and diagnostic skills on the part of the provider resulting in more expedient 
treatment and relief for the patient. 
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Anatomy 
The pelvic diaphragm consists of the levator ani and coccygeus muscles along 
with their superior and inferior layers of fasciae. The levator ani are a group of striated 
muscles that includes the puborectalis, pubococcygeus and ileoccoccygeus. The 
coccygeus, piriformis and obturator internus muscles also contribute to the pelvic floor 
(Andromanakos, Kouraklis, & Alkiviadis, 2011). The pelvic floor muscles contract and 
relax, allowing for defecation, micturition, parturition, sexual function, urinary and fecal 
continence. These muscles provide a critical component of pelvic stability and pelvic 
organ support. The pelvic floor musculature has two components: the viscoelastic 
component, which is independent of nervous activity, and the contractile component, 
which is caused by activation of motor units. It is possible that abnormalities of both the 
viscoelastic and the contractile component may contribute to the abnormality in pelvic 
floor muscle tension (Wehbe, Whitmore & Kellogg-Spadt, 2010).  
Definition 
 HTPFD was first described in the literature by Simpson in 1859, though he 
referred to it somewhat inaccurately as coccygodynia. This condition is more often 
reported in the colorectal literature and referred to as multiple entities including spastic 
piriformis (Thiele, 1937), coccygeus-levator spasm syndrome (Paradis & Marganoff, 
1969), tension myalgia of the pelvic floor (Sinaki et al, 1977), levator syndrome (Grant, 
Salvati & Rubin, 1975) and spastic pelvic floor syndrome (Bleijenberg & Kuijpers, 
1987). More recently the urologic and gynecologic literature has referred to it as 
overactive pelvic floor muscles (Messelink et al., 2005), levator ani spasm/syndrome 
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(Hull & Corton 2009), pelvic floor muscle spasm (Bendana et al., 2009) and high tone 
pelvic floor muscle dysfunction (Finamore, 2008). 
In 1937, Thiele described coccygodynia as an entity characterized by pain to the 
coccyx associated with levator ani and coccygeus muscle spasm. He noted spastic pelvic 
floor musculature upon digital rectal exam in 64 of 69 patients with coccygeal pain. He 
further characterized coccygodynia based on a retrospective review of 324 cases in 1963. 
These patients reported lower sacral and coccygeal pain often exacerbated by prolonged 
sitting; however, few reported pain with direct palpation of the coccyx (Thiele, 1937). 
These symptoms are more consistent with a diagnosis of HTPFD rather than 
coccygodynia. 
The term coccygeus-levator spasm syndrome was used by Paradis and Marganoff 
in 1969 to describe patients with pelvic floor spasm and rectal pain. Their exam revealed 
tenderness with palpation of sites adjacent to the coccyx and ischial spine, suggesting 
ligament, tendon and myofascial involvement, rather than the muscles themselves. 
Infection and trauma were ruled out as etiological factors in this patient population 
(Paradis & Marganoff, 1969). 
Grant et al. (1975) used the term levator ani syndrome to describe patients with 
symptoms of pelvic floor muscle tenderness and spasm. Most reported symptoms of 
rectal pain/discomfort of unknown etiology. They noted that tenderness upon motion of 
the coccyx is not an important part of this syndrome. Therefore, the term “coccygodynia” 
should not be used. The authors also reported that the syndrome affected women more 
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than men and occurred most often in the fourth, fifth and sixth decades of life (Grant, 
Salvati, & Rubin, 1975). 
Tension myalgia of the pelvic floor was a term used by Sinaki et al. (1977) to 
describe patients with spastic pelvic floor muscles. They reported common symptoms 
including low back pain (82%), pelvic pressure (64%) and increased pain with sitting 
(88%). The authors also reported a relationship between habitual contracting of pelvic 
floor muscles and hypochondriasis (Sinaki, Merritt, & Stillwell, 1977). 
 More recently, the International Continence Society defined overactive pelvic 
floor muscles as a condition in which the pelvic floor muscles do not relax or may even 
contract when relaxation is functionally needed for example during micturition or 
defecation. They describe it as a condition based on symptoms such as voiding problems, 
obstructed defecation or dyspareunia and the absence of voluntary pelvic floor muscle 
relaxation (Messelink et al., 2005). For the purpose of this review, this condition will be 
referred to as high tone pelvic floor dysfunction (HTPFD).  
Prevalence 
HTPFD is thought to affect more than 10 million women in the United States 
alone with greater than 50% between the ages of 30 and 60 years (Andromanakos et al, 
2008). Previous studies have found that myofascial pain and HTPFD are present in as 
many as 87% of patients with interstitial cystitis (IC) and/or chronic pain syndromes 
(CPS) (Peters, Carrico, Kalinowski, Ibrahim, & Diokno, 2007). In the colorectal 
literature, overactive pelvic floor muscles are referred to as tension myalgia of the pelvic 
floor and levator ani syndrome with a reported prevalence of approximately 6.6% of the 
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general population (Andromanakos, et al., 2011). Abnormal function of the pelvic floor 
musculature is seen in an estimated 70% of women with genitourinary, bowel and sexual 
disorders (Wehbe, Whitmore, & Kellogg-Spadt, 2010). The etiology of the disease is 
thought to be multifactorial and therefore often goes unreported.  
Clinical Features 
HTPFD occurs when the muscles are chronically tense or in spasm resulting in 
loss of ability to contract and relax. This can occur as an entity in and of itself but is more 
commonly associated with other conditions such as urinary urgency/frequency and 
incontinence (Abbott, 2009; Clemens et al., 2000), urinary retention (Finamore et al., 
2008), painful bladder syndrome, vulvar vestibulitis, irritable bowel syndrome, 
endometriosis, pelvic pain (Andromanakos et al., 2011), fecal incontinence 
(Andromanakos et al., 2008) and constipation of obstructed defecation (Thiele, 1963). It 
can be difficult to discern if the muscle spasm developed first or as a result of any of the 
aforementioned conditions. Commonly reported urinary symptoms include urinary 
frequency, a sensation of incomplete bladder emptying, urinary hesitancy, varied force of 
urinary stream and discomfort with bladder filling (Finamore, 2008). Gynecological 
symptoms may present as deep dyspareunia, pain with orgasm and pelvic discomfort the 
day following intercourse (Tu, As-Sanie, & Steege, 2005). Much of the colorectal 
literature reports patients presenting with complaints of chronic constipation, pain with 
defecation, pain with prolonged sitting on a hard surface or a sensation of “sitting on a 
golf ball” (Oyama et al., 2004). Musculoskeletal symptoms can include low back pain 
and pain radiating to inner thighs (Tu, et al., 2005). Determining the chronological order 
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of symptom onset can be a challenge due to the amount of time that often passes prior to 
the patient receiving the correct diagnosis. 
Events that are considered risk factors leading to chronic tensing of the pelvic 
floor muscles include pelvic muscle strain from trauma such as childbirth, pelvic surgery, 
sports injury, bicycle riding, sexual abuse; urinary and fecal incontinence, chronic 
constipation and inflammation of pelvic organs from conditions such as interstitial 
cystitis, vaginitis, endometriosis, anal fissures; and finally referred pain from nearby 
muscles, nerves and viscera (Finamore, 2008). Frequent painful voiding as well as 
anticipation of genital pain during intercourse can result in pelvic floor muscle guarding 
that, over time, can lead to sustained shortening and spasm of the muscle (Wehbe et al, 
2010). 
Assessment 
Digital vaginal exam of the pelvic floor muscle bed is commonly used to assess 
for HTPFD in women. The focus of this exam is the evaluation of the levator ani and 
obturator internus muscles for spasm. The examiner evaluates for taut muscle bands, 
nodules within the muscles and pain/tenderness using firm yet gentle pressure (Fitzgerald 
et al., 2011; Hull & Corton, 2009). Examination of the pelvic floor muscles is performed 
with the patient in a lithotomy position while the examiner pictures the vagina on the face 
of a clock. The examiner places a gloved index finger one inch or to the first knuckle 
inside the distal vagina. The pubococcygeus muscle can be felt from 7 to 11 o’clock on 
the left and 1 to 5 o’clock of the right.  This is followed by deeper insertion of the finger 
into the vagina with the palpation of the iliococcygeus muscle from the 4 to 8 o’clock 
position. Evaluation of the obturator internus muscle can then be palpated at the 10 and 2 
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o’clock position. Patients with tenderness on palpation of any of these trigger points are 
highly likely to have a diagnosis of HTPFD (Chiarioni, Nardo, Vantini, Romito, & 
Whitehead, 2010; C. M. Fitzgerald et al., 2011). Examination of the pelvic floor needs to 
be standardized so that clinicians can make reliable clinical decisions across patients and 
across time not only in the initial diagnosis but also in the evaluation of the patient's 
response to treatment. A more accurate diagnosis may also lead to more appropriate 
subgroupings; visceral versus musculoskeletal which could in turn lead to more 
appropriate management by healthcare providers (Hull & Corton, 2009). 
Assessment of pelvic floor muscle strength is important to determine a woman's 
ability to isolate, contract and relax the pelvic floor muscles. Chronically tense pelvic 
floor muscles lose their ability to contract and relax. Once patients with HTPFD learn to 
isolate these muscles, they can be trained to relax them. The quantification of a 
contraction is problematic and to date there is no validated scale to quantify contractions 
of the pelvic floor muscles.  A correct contraction can be observed clinically (Kegel, 
1948), by ultrasound (Beco, Sulu, & Schaaps, 1987; Dietz, Jarvis, & Vancaillie, 2002; 
Jarvis, Abbott, Lenart, Steensma, & Vancaillie, 2004)  or with dynamic magnetic 
resonance imaging (Stoker, Halligan, & Bartram, 2001). The Oxford scale is used most 
frequently, but inter-observer variability has been reported to be high. Although vaginal 
assessment of pelvic floor muscle strength may be internally consistent, reliability and 
reproducibility between examiners varies (Bø & Finckenhagen, 2001). Objective 
measurements such as perineometry, perineal ultrasound and EMG are consistent in 
providing evidence of contraction but none are able to assess true strength (Rogalski, 
Kellogg-Spadt, Hoffmann, Fariello, & Whitmore, 2010). The Pelvic Floor Clinical 
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Assessment Group of the International Continence Society is an international group of 
interdisciplinary experts with an interest in the standardization of terminology of pelvic 
floor muscle function and dysfunction.  This world-renowned medical committee 
recommends the following method of examining pelvic floor muscle strength in women: 
The patient is placed in a supine position with hips and knees flexed. One gloved, 
lubricated finger is introduced into the vagina and the patient is asked to contract the 
muscles around the examiners finger. Instructing the patient to “lift” and “squeeze” may 
be necessary if the patient is having difficulty isolating the pelvic floor muscles. There is 
no gold standard scale to refer to when quantifying pelvic floor strength, therefore this 
group does not recommend anything more than the simplest classification of absent, 
weak, normal or strong (Messelink et al., 2005). 
Treatment 
 The aim of treatment for HTPFD is to relax the pelvic floor musculature and 
restore proper functioning of the pelvic floor organs. Currently accepted therapies include 
pelvic floor muscle massage to elongate musculature and relieve pain, benzodiazepines 
for their antispasmotic activity in muscle hypertonis and pelvic floor therapy/biofeedback 
with or without electrogalvanic stimulation (Tu, et al., 2005). Trigger point injections 
have also proven beneficial in patients with chronically contracted pelvic floor 
musculature.  
Manual Therapy 
Direct pelvic muscle massage is well documented in the literature as an effective 
treatment for HTPFD. This is often performed by a physical therapist specializing in the 
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treatment of PFD. The aim of direct massage of the pelvic floor is to elongate shortened 
muscles and decrease high tone spasm (M. P. Fitzgerald et al., 2009; Lukban & 
Whitmore, 2002). Thiele reported a case series of 31 patients with pelvic muscle pain 
who underwent a series of direct transrectal massage of the pelvic floor muscles. 
Nineteen subjects (61.3%) reported complete resolution of their pain and 17 (35.5%) 
showed improvement after multiple sessions of therapy (Thiele, 1937). Thiele combined 
this data with eight other proctologists using the same technique and reported 93.7% 
improvement in a total of 80 participants (Thiele, 1963). 
 Manual therapy of the pelvic floor in patients with genitourinary disorders has 
also proven to be successful. Weiss used a transvaginal or transrectal approach to 10 
patients with interstitial cystitis (IC) and 42 patients with urinary urgency/frequency. The 
treatment included pelvic floor muscle compression, stretching and right angle 
strumming with the simultaneous use of external myofascial release or application of heat 
to facilitate greater muscle relaxation. Seventy percent of the IC patients and 83% of the 
urgency/frequency group reported greater than 50% improvement in their symptoms as 
determined by patient-completed questionnaires (Weiss, 2001). An unspecified number 
of these patients also had trigger points injected as part of their therapy. Whether the 
impact of the treatment favored the pain symptoms as opposed to urologic function was 
not made clear. 
 Oyama et al., (2004) evaluated the effectiveness of the modified Thiele’s massage 
in 21 women with IC. The study participants received weekly transvaginal massage for 
six weeks with symptom evaluation before, immediately after, and 4.5 months following 
treatment. The results indicated statistically significant improvement in the mean 
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symptom and problem indices of the O'Leary – Sant Questionnaire and the SF-12 
Quality-of-Life scale. The researchers reported improvement in irritative voiding 
symptoms as well as a decrease in pelvic floor muscle tone (Oyama, et al., 2004).  
A recent randomized clinical trial was designed to compare two methods of 
manual therapy in patients with urological chronic pelvic pain syndromes including 
chronic prostatitis/chronic pelvic pain syndrome or IC. Twenty four patients were 
randomized to global therapeutic massage, 23 to myofascial physical therapy and 94% 
completed the study.  The overall response rate of 57% in the myofascial physical 
therapy group was significantly higher than the global therapeutic group (21%) 
suggesting myofascial therapy is a meaningful treatment option for HTPFD with 
associated pelvic pain (Fitzgerald, et al., 2009).  
Benzodiazepines 
Although muscle relaxants have been suggested to be effective in the treatment of 
muscle spasm, only two studies have evaluated the use of diazepam for the relief of pain 
in patients with HTPFD. McGivney and Cleveland (1965) reported that oral 
administration of diazepam for an average period of 11 weeks produced marked relief of 
symptoms of pelvic pain. Of the 64 participants, 80% subjectively reported marked relief, 
14% had minimal relief and 6% were uncertain (McGivney & Cleveland, 1965). A 2010 
retrospective chart review evaluating intravaginal diazepam (10 mg suppositories) as 
adjunctive treatment for dyspareunia related to pelvic muscle spasm showed that 25 of 26 
patients reported improvement with suppository use. Pelvic floor muscle tone and pain 
were assessed by palpation and perineometry. Sexual pain was objectively rated by 
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Female Sexual Function Index and the Visual Analog Scale for Pain. The authors 
concluded that vaginal valium suppositories gave a clinically significant improvement in 
the treatment of HTPFD compared with the usual treatment regimen alone (Rogalski, et 
al., 2010). 
Crisp et al., (2013) enrolled 21 subjects into a triple-blinded placebo-controlled 
randomized trial to determine if 10 mg diazepam suppositories improved resting pelvic 
floor electromyography (EMG) compared with placebo. The researchers discovered no 
difference in any of the resting vaginal EMG assessments at any time point within 
subjects or between groups and no differences were noted in any of the validated 
questionnaires. 
Trigger Point Injections 
In addition, trigger point injections into chronically contracted pelvic floor 
musculature has been shown to be helpful in the relief of pelvic pain. Trigger point 
injections are typically used as adjuvant therapy to pharmacotherapy, physical therapy 
and behavioral therapy. Therefore, it is recommended they not be used as first-line 
treatment, or as monotherapy for chronic pelvic pain. A myriad of medications and 
techniques may be used for administering injections. The most common are 
intramuscular infiltration with a local anesthetic such as lidocaine or bupivicaine 
(Moldwin, R.M. & Fariello; 2013).  
Langford, Udvari, Nagy & Ghonieum (2007) studied the role of trigger point 
injections in eighteen women with pelvic floor muscle spasm and chronic pelvic pain of 
at least six months duration. The trigger points were identified by digital intravaginal 
palpation of the levator ani muscles and mixture of 0.25% bupivacaine, 2% lidocaine, and 
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triamcinolone was injected. Thirteen of eighteen women improved after the first trigger 
point injection with a mean follow up of three months, resulting in a comprehensive 
success rate of 72%; six of 18 women (33%) reported complete resolution of their pain.  
Fouad, Chen, Pettit, & Micallef (2015) conducted a retrospective review of 75 
patients who underwent outpatient transvaginal trigger point injections for HTPFD from 
2007- 2015. VAS scores were recorded before and 1-2 weeks after treatment. 
Improvement was noted via VAS in 63% of patients (p <.0001). Twenty seven percent of 
patients underwent repeat trigger point injection and 16% needed Botox injection. 
 A number of studies have been published revealing the effectiveness of trigger 
point injections of onabotulinumtoxinA (BoNTA) resulting in muscle paralysis and 
subsequent relief of pelvic pain due to HTPFD (Abbott, Jarvis, Lyons, Thomson, & 
Vancaille, 2006; Jarvis, et al., 2004; Rao, Paulson, Mata, & Zimmerman, 2009; Romito et 
al., 2004; Thomson, Jarvis, Lenart, Abbott, & Vancaillie, 2005). Urinary incontinence 
related to neurogenic detrusor overactivity is currently the only approved indication for 
BoNTA into the female pelvis. Other supported off-label uses include: idiopathic detrusor 
overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, 
HTPFD, anal fissure, anismus, and functional anal pain (El-Khawand, Wehbe, & 
Whitmore, 2013). BoNTA may effectively and safely be used in many conditions of the 
female pelvis. More high quality research is needed to better clarify its role in the 
therapeutic algorithm for those indications. 
Adelowo, Hacker, Shapiro, Modest, & Elkadry. (2013) published a retrospective 
cohort study of 31 women who underwent intralevator Botox injection between 2005 and 
2010 for refractory myofascial pelvic pain. Primary outcomes were self-reported pain on 
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palpation and symptom improvement. Secondary outcomes included postinjection 
complications and a second injection. The researchers concluded that intralevator 
injection of Botox demonstrates effectiveness in women with refractory myofascial 
pelvic pain with few self-limiting adverse effects. However, this study is limited by its 
retrospective design and lack of validated questionnaires.  
Nesbitt-Hawes, Won, Jarvis, Lyons, Vancaillie, & Abbott, (2013) published a 
prospective study to report the outcomes of pain and vaginal pressures of successive 
botulinum toxin type A injections for women with objective HTPFD and a two-year 
history of pelvic pain. Between 2005 and 2008, 37 women underwent injection of 100 IU 
of botulinum toxin type A into the levator ani muscles. Outcomes were determined with 
use of VAS and vaginal pressure measured by vaginal manometry, at 0, 4, 12 and 26 
weeks from each injection. Twenty six women (70%) had one injection of BoTNA and 
11 (30%) had two or more injections. They reported that both single and repeated 
injections demonstrated a statistically significant reduction in dyspareunia (p = .001), 
non-menstrual pelvic pain (p = .04), as well as vaginal pressures (p = .02). No statistically 
significant difference in dysmenorrhea or dyschesia was observed for either group. The 
authors concluded that women who have had benefit from a single injection of botulinum 
toxin type A can be reassured that if symptoms reoccur, repeated injections can be 
expected to be equally efficacious. 
Bertolasi, Frasson, Cappelletti, Vicentini, Bordignon, & Graziottin, (2013) 
prospectively recruited 39 women whom failed standard treatment for vaginismus and 
vulvar vestibular syndrome to investigate whether BoTNA offered symptom 
improvement. Validated questionnaires were administered and pelvic floor EMG was 
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recorded. The primary outcome measures (the possibility of having sexual intercourse, 
and levator ani EMG hyperactivity) both improved, as did the QOL and sexual 
functioning scores. When follow-up ended, 63.2% of the patients completely recovered 
from vaginismus and vulvar vestibular syndrome, 15.4% still needed reinjections 
(censored), and 15.4% had dropped out. 
In one pilot prospective cohort study, BoNTA was injected into the levator ani 
muscles of twelve women with a two-year history of chronic pelvic pain associated with 
HTPFD. Median visual analog scale pain scores were significantly improved for 
dyspareunia and dysmenorrhea. Both QOL and sexual activity scores were markedly 
improved (Jarvis, et al., 2004). A randomized control trial by Abbot et al., (2006) 
revealed that BoTNA injections into the pelvic floor muscles of thirty women with 
chronic pelvic pain had significantly greater improvement in dyspareunia, pelvic pain and 
pressure than the non-treatment group. Bhide et al., (2015) published a systematic review 
of the literature up to 2012 on the use of BoNTA in the treatment of pelvic muscle spasm 
and concluded that although data remained scarce, preliminary results are encouraging.  
 Morrissey et al., (2015) conducted a prospective pilot study of women with 
chronic pelvic pain and HTPFD who failed conventional therapy. BoTNA injections were 
performed from a transperineal approach, using needle electromyography guidance to 
localize spastic pelvic floor muscles. Data were collected at baseline, 4, 8, 12, and 24 
weeks after injections including Visual Analog Scale (VAS) scores for pain and 
dyspareunia; validated questionnaires for symptoms, QOL, and sexual function; Global 
Response Assessment scale for pelvic pain; digital examination of PFM for tone and 
tenderness; and vaginal manometry. Side effects were also recorded. Out of 28 women 
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who enrolled in the study, 21 completed the 6-month follow-up and qualified for 
analysis. Overall, 61.9% of subjects reported improvement on Global Response 
Assessment at 4 weeks and 80.9% at 8, 12, and 24 weeks post injection, compared with 
baseline. Of the subjects who were sexually active at baseline, 58.8% (10/17), 68.8% 
(11/16), 80% (12/15), and 83.3% (15/18) reported less dyspareunia at 4, 8, 12, and 24 
weeks, respectively. Sexual dysfunction as measured by the Female Sexual Distress Scale 
significantly improved at 8 weeks (P = 0.005), 12 weeks (P = 0.006), and 24 weeks (P < 
0.001) compared with baseline. The Short-Form 12 Health Survey (SF-12) showed 
improved QoL in the physical composite score at all post injections visits (P < 0.05), and 
in the mental composite score at both 12 and 24 weeks (P = 0.012). Vaginal manometry 
demonstrated significant decrease in resting pressures and in maximum contraction 
pressures at all follow-up visits (P < 0.05). Digital assessment of PFM (on a scale from 0 
to 4) showed decreased tenderness on all visits (P < 0.001) compared with baseline. 
Reported postinjection adverse effects included worsening of the following preexisting 
conditions: constipation (28.6%), stress urinary incontinence (4.8%), fecal incontinence 
(4.8%), and new onset stress urinary incontinence (4.8%). 
Electrogalvanic stimulation 
 EGS of the pelvic floor musculature has been shown to decrease muscle spasm by 
fatigue after sustained muscle contraction. This, in addition to motor neuron suppression 
is believed to be the mechanism of pain relief in patients with pelvic/rectal pain 
associated with HTPFD (Lukban & Whitmore, 2002). This method of treatment employs 
painless, high voltage direct current to the pelvic floor muscles with use of vaginal or 
anal probe. This method is not to be confused with electrical stimulation via an external 
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route which employs low voltage alternating current to facilitate muscle relaxation. EGS 
for the treatment of HTPFD was first described by Sohn et al., (1982) in a retrospective 
review of sixty women and twenty men with symptoms of pelvic/rectal pain. The patients 
were treated with rectal EGS for one hour per day over a period of 3-10 days. Complete 
resolution of symptoms in 69% of the patients was reported with no recurrence during 6 
to 30 months follow up. In 21% of the participants, complete resolution of pain was 
reported with a return of symptoms at follow up. The authors concluded that because this 
therapy is simple, safe and not associated with significant side effects, it should be used 
as a primary modality of therapy for those with a diagnosis of HTPFD (Sohn, Weinstein, 
& Robbins, 1982). 
A similar study was conducted by Nicosia and Abcarian (1985) in the treatment 
of 32 women and 13 men who underwent twenty minutes of intra-anal electrogalvanic 
stimulation therapy every other day for an average of five treatments. Total relief of 
pelvic/rectal pain was reported by 80% of the participants. The authors concluded that 
electrical stimulation is the treatment of choice for HTPFD because it can be 
standardized, is well tolerated and is over 90% effective (Nicosia & Abcarian, 1985). 
Oliver et al. (1985) reviewed the records of ninety patients with HTPFD who 
underwent a total of three rectal EGS treatments. All sessions lasted 60 minutes within a 
period of ten days. Prior to beginning EGS, conservative treatments were tried and failure 
of the conservative regimen was part of the inclusion criteria of this study (Oliver, Rubin, 
Salvati, & Eisenstat, 1985). Relief or improvement of symptoms was reported by 77% of 
these patients. Likewise, Morris and Newton (1987) published a retrospective review of 
23 women and five men with diagnosis of HTPFD who underwent rectal EGS therapy. 
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“Relief” of pain was reported in 75% of the participants with an average of six 
treatments. This study was unique in that it used a VAS to quantitatively measure the 
outcomes (Morris & Newton, 1987). 
 Intra-anal EGS was performed on 20 patients with a diagnosis of HTPFD by 
Billingham et al., (1987). The participants underwent a series of one to twelve 15-60 
minute treatments with a reported 60% improvement immediately following therapy. 
Ongoing improvement several weeks to several months after treatment was reported by 
25% of the participants. There were eleven females and nine males in this study ranging 
in age from 32 to 88 years. All had failed previous treatment for symptoms of rectal pain 
(Billingham, Isler, Friend, & Hostetler, 1987). 
Patients undergoing intra-anal EGS stimulation for a diagnosis of HTPFD 
between 1985 and 1991 were studied by Hull, Milsom and Church et al. (1993) to 
determine the long term benefits of this treatment modality. Each of the fifty two patients 
underwent three treatments every other day with additional treatments performed per 
patient request. The authors obtained follow up data via phone call (n=31) or patient 
medical record (n=11). Of these patients 27% of the chart follow ups reported treatment 
benefit seven weeks after completion of therapy and 16% of those undergoing phone 
interview reported ongoing improvement after three years (Hull et al., 1993). 
Fitzwater, Kuehl & Schrier (2003) conducted a retrospective cohort study of 50 
women treated with vaginal EGS for HTPFD. Demographic data was collected including, 
mean age, parity, education, marital status and race. Most subjects underwent three or 
less treatments with 68% reporting improvement in symptoms at completion of therapy. 
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Using survival analysis, the authors reported 51% of patients had persistent improvement 
thirty weeks after treatment.  They determined that there was no significant difference in 
age, race, parity or education in patients reporting a sustained benefit from treatment and 
those reporting no benefit (Fitzwater et al., 2003). 
Biofeedback and EGS Combined 
 EGS combined with biofeedback has been shown to be effective in the treatment 
of HTPFD but is poorly described in the literature. Soe, Choe, Lee & Kim (2005) 
reported improvement in symptoms of vaginismus in twelve women who underwent 
transvaginal EGS and biofeedback. All twelve women were able to achieve satisfactory 
vaginal intercourse following eight weeks of therapy. Bendana et al. (2009) conducted a 
retrospective review of 52 women who presented to a urology clinic with symptoms of 
urinary urgency/frequency associated with HTPFD. The women were treated with six 
weekly one hour sessions undergoing biofeedback and vaginal EGS. Symptom 
improvement of 64.5% was reported immediately following treatment and at three 
months. Symptom severity demonstrated statistically significant improvement and effect 
on daily life (Bendana et al., 2009).  
 Starr et al. (2013) published a retrospective review of 728 women who underwent 
biofeedback and EGS with a reported mean improvement of 80% in bladder, bowel and 
pelvic pain complaints. However, these researchers did not report the percentage of these 
women with HTPFD.  
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Treatment Limitations/Recommendations 
There are significant limitations in the existing literature regarding treatment of 
HTPFD leaving little evidence to guide the clinician. The vast majority of the 
aforementioned studies failed to use a control group, possibly overestimating their 
effectiveness and relegating their scientific use only to hypothesis generation for future 
studies. Also, many used subjective outcomes which may not represent meaningful 
outcomes in different population. Most failed to use quantitative outcome measures such 
as quality of life questionnaires and visual analog pain scales, ignoring the need for 
careful assessment of clinical outcomes. Furthermore, the majority of the studies 
combined men and women together in analysis, ignoring the relevance of gender specific 
causes for HTPFD.  
 Treatment recommendation for patients with HTPFD can depend on several 
factors including availability of treatment, cost and patient motivation/willingness to take 
an active role in their care. A therapy that is simple, safe and not associated with 
significant side effects should be used as a primary modality such as pelvic muscle 
massage or EGS with or without biofeedback. In order to achieve a successful outcome, 
both treatments require an average of 6-8 sessions with a therapist and a willingness to 
perform simple exercises every day. Availability of either treatment may be a challenge 
as these therapies are often not performed in smaller communities. Trigger point 
injections have proven useful and should be considered if less invasive therapies fail. 
Vaginal diazepam suppositories can be used as an adjunct treatment or when the patient 
does not have access to other modalities. Cost should always be considered as 
reimbursement varies depending on the patient insurance plan. Finally, each patient 
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should be given the options for treatment and allowed to take part in the treatment 
decision. 
Discussion 
 Normal function of the pelvic floor musculature is a critical component in 
maintaining pelvic stability, pelvic organ support and normal function of the female 
pelvic organs. Voluntary control of this muscle group is essential to allow for defecation, 
micturition, parturition, sexual function, urinary and fecal continence. HTPFD can lead to 
an inability to relax the pelvic floor muscles, often resulting in dysfunction of more than 
one organ system. Because HTPFD is often overlooked in clinical practice and because it 
contributes to costly conditions such as urinary incontinence, constipation and pelvic 
pain, it is important for the health care community to focus on heightening clinician 
awareness of the condition, standardizing pelvic floor terminology and pelvic muscle 
exam and educating providers about available treatments. 
HTPFD is referred to as multiple entities in the literature and no standardized 
terminology of pelvic floor muscle dysfunction or diagnostic exam was found upon 
completion of this review. Basic studies on the different aspects of the pelvic floor 
muscles were limited due in part to the difficulty in defining the different aspects of this 
muscle group and their function. Even if they were defined, they could not be easily 
measured and if they were measurable there is no agreement as to normal values.  
Including HTPFD in the differential diagnosis is important when assessing a 
patient presenting with symptoms of PFD. Common conditions such as constipation, 
voiding dysfunction, urinary incontinence and pelvic pain can be associated with this 
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condition and are commonly seen in family practice settings as well as gerontology, 
gastroenterology, colorectal, urology and gynecology. Publication of review articles in 
associated professional journals will increase clinician awareness of this condition and 
potentially lead to more accurate and timely diagnosis and treatment, resulting in 
improved patient outcomes and saving of health care dollars.  
Standardization of pelvic floor muscle assessment is necessary to provide the 
examiner with information regarding normal or abnormal findings that might suggest a 
muscular basis for the patient’s symptoms. This will allow the provider to make reliable 
decisions across patients and across time not only with the initial diagnosis but also in 
evaluation of the treatment response. Professional organizations such as the International 
Continence Society and International Urogynecology meet annually to discuss such 
issues and progress is being made in standardization of terminology and patient exam. 
Clearly increased scientific rigor is needed to guide management of HTPFD and 
establishment of diagnostic criteria should be a priority.  Further randomized controlled 
studies are necessary to determine comprehensive exam methods, effective treatment 
modalities and evaluation of treatment response. Validated quality of life questionnaires 
are recommended to quantitatively measure outcomes. Publication of case series and 
individual case studies would be useful to quickly bring this condition to the attention of 
clinicians who may otherwise not include HTPFD as a differential diagnosis. Priority 
should be given to the aforementioned recommendations so that millions of women can 
be quickly diagnosed and treated, resulting in saving of health care dollars and improved 
patient outcomes.  
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CHAPTER THREE 
Methods/proposal 
PROPOSED STUDY 
For this proposed study, the researcher will conduct a secondary analysis of a 
longitudinal data set of 406 women who presented for comprehensive pelvic floor 
rehabilitation by an APRN for symptoms of pelvic floor dysfunction (PFD). This type of 
comprehensive treatment analysis is lacking in the literature and to date only 
retrospective or underpowered studies have been published (Hay-Smith et al., 2015). 
Analyzing and reporting these data will advance the literature on complex outpatient 
management of women with symptoms of PFD. In addition, analyzing the demographic 
data of these women will glean valuable information regarding who is most likely to 
benefit from this treatment regimen, assisting providers in treatment recommendation.  
Data analysis will include the Pelvic Floor Distress Inventory (PFDI-20) and the 
Pelvic Floor Impact Questionnaire (PFIQ-7) questionnaires administered at baseline, 
completion of treatment, six months and one year to determine QOL changes associated 
with the intervention. Pelvic Floor Therapy Evaluation forms which included visual 
analog scales (VAS) administered at return treatment sessions, six months and one year 
will also be analyzed to determine patient compliance with pelvic muscle exercises and 
recommended bowel treatment plan. Perceived improvement in urinary, defecatory and 
pelvic pain symptoms will be tracked via the VAS (see appendix C). This data base is 
ongoing and only data collected up to February 2016 will be analyzed for the purpose of 
this study. 
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Instrumentation 
Three valid and reliable measures were collected for the longitudinal data set to 
measure the effectiveness of treatment and impact of continuance of learned behavior 
modification on symptom improvement and quality of life (QOL). The PFDI-20 (see 
Appendix A) and PFIQ-7 (see Appendix B) questionnaires were used to monitor 
treatment effect on QOL of this longitudinal study. These validated questionnaires are 
considered the most rigorous instruments available in assessing life impact and QOL of 
women with symptoms of PFD. The intended population of both questionnaires includes 
women with disorders of the pelvic floor including urinary incontinence, pelvic organ 
prolapse and anal incontinence. The strength of the PFDI-20 is that it is a short form of 
the PFDI that gives a comprehensive assessment of the effect of pelvic floor disorders on 
the QOL of women, rather than assessing just one aspect of pelvic floor function such as 
urinary incontinence. The PFIQ-7 is the short form of the PFIQ and the only 
questionnaire that assesses life impact in women with pelvic floor disorders. These 
questionnaires have been translated and validated in several languages, allowing the use 
of a common tool for evaluation of PFD in different populations and cultures (De Tayrac, 
Deval, Fernandez, & Mares. 2007; Kaplan, Sut, N., & Sut, H. 2012; Teleman, Stenzelius, 
Iorizzo, & Jakobsson,  2011).   
The validity and responsiveness of PFDI-20 and PFIQ-7 was evaluated in four 
multi-center studies conducted to develop conversion formulas between the short and 
long versions. Barber et al (2011) looked at 1006 participants in these prospective studies 
of pelvic floor disorders who completed the long versions of the PFDI, PFIQ at baseline 
and three and twelve months after treatment. Responses were used to calculate scores for 
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the short versions and correlations were calculated between scale versions using 
Pearson’s correlation coefficient comparing their relative responsiveness using the 
standardized response mean. The researchers found that the PFDI-20 and PFIQ-7 scale 
scores demonstrated excellent correlations with their long versions and similar 
responsiveness at three and twelve months. Responsiveness was good to excellent for 
PFDI-20 urinary and prolapse scales (SRM -0.71 and -0.85 respectively), moderate for 
PFDI-20 colorectal scale (SRM-0.73 to -1.09) and each of the PFIQ-7 scales summary 
scores (-0.21 to -0.90). Conversion formulas demonstrated excellent goodness of fit. The 
short forms provide a reliable and valid alternative in situations where reduced response 
burden is desired.  
The VAS is widely used due to its simplicity and adaptability to a broad range of 
populations and settings. It is sensitive to small changes and is of most value when 
measuring changes within individuals, versus comparisons across a group (Hawker, 
Mian, Kendzerska, & French, 2011). This instrument was particularly useful in 
evaluating subject perceived symptom improvement at each session and aided the APRN 
in determining course of treatment (see Appendix C). 
Pelvic Floor Distress Inventory-20 (PFDI-20)  
The PFDI-20 is both a symptom inventory and a measure of the degree of bother 
and distress (QOL) caused by pelvic floor symptoms. It is a short form version of the 
Pelvic Floor Distress Inventory. The PFDI-20 includes 20 questions and three scales, 
Urinary Distress Inventory, Pelvic Organ Prolapse Distress Inventory, and Colorectal 
Anal Distress Inventory. Each of the three scales are scored from 0 (least distress) to 100 
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(greatest distress). The scores are weighted and the sum of the scores of these three scales 
serves as the overall summary score of the PFDI-20 which ranges from 0 to 300. (Barber, 
Walters, & Bump, 2005). 
The PFDI-20 has good test-retest reliability (interclass coefficient r=.86, p< .001). 
Each of the three scales (urinary distress inventory, pelvic organ prolapse distress 
inventory and colorectal-anal distress inventory) demonstrates significant correlation with 
their long-form scales (r= .86, r= .92, r=.93, respectively, p<.0001). The PFDI-20 has 
strong construct validity as it demonstrates a significant association with appropriate 
measures of symptom severity and pelvic floor diagnosis (Barber et al., 2011). 
Pelvic Floor Impact Questionnaire-7 (PFIQ-7) 
The PFIQ-7 is a shortened version of the PFIQ and is used to assess life impact, 
i.e. QOL, in women with pelvic floor disorders. It includes all of the Incontinence Impact 
Questionnaire-7 as well as items related to other pelvic floor disorders. The PFIQ-7 
consists of three scales of seven questions each taken from the Urinary Impact 
Questionnaire, the Pelvic Organ Prolapse Impact Questionnaire and the Colorectal-Anal 
Impact Questionnaire. The three scales are scored from 0 (least impact) to 100 (greatest 
impact) and an overall summary score (0-300). Each of the three scales correlates highly 
with their long forms (r=.96, r=.96, r=.94, respectively, p<.0001). This questionnaire 
demonstrates construct validity as it demonstrates a significant association with 
appropriate measures of symptom severity and pelvic floor diagnosis. The PFIQ-7 
demonstrates moderate responsiveness (Barber et al., 2011).   
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Visual Analog Scale 
Three VAS scales were used to measure perceived improvement in urinary, 
defecatory and pelvic pain symptoms following initial treatment. The VAS is a straight 
horizontal line measuring 100mm. The ends are defined as the extreme limits of the 
parameters to be measured (urinary, defecatory and pelvic pain symptoms) oriented from 
left (worse) to the right (best). 
The patient is asked to mark on the line the point that they feel represents their 
perception of their current state. The score is determined by measuring in mm from the 
left end of the line to the point that the patient marks. The VAS requires little training to 
administer and score and has been found to be acceptable to patients. The test-retest 
reliability has been shown to be good, but higher among literate (r=0.94, p=0.001) than 
illiterate patients (r=.71, p=0.001) (Hawker et al., 2011). 
Demographic and Compliance Data 
Demographic data will be collected and analyzed in an attempt to reveal predictor 
variables associated with treatment success and failure. The information collected by the 
APRN at the initial visit will include patient demographics, medical, surgical and 
obstetrical history, pelvic organ prolapse stage and medications.  Data will be collected 
via the Pelvic Floor Therapy Evaluation form and recorded at subsequent visits by the 
APRN regarding compliance with behavior modifications to assist in determining 
predictor variables for long term treatment success. The Pelvic Floor Evaluation form 
designed specifically for patients returning for the second through the final visit and 
includes compliance with pelvic muscle exercises (number of times per day exercises 
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performed), compliance with the recommended bowel treatment program(frequency of 
BM, straining and use of bulk forming fiber such as psyllium), use of vaginal estrogen if 
indicated (dosage and frequency of use) and in some cases adherence to prescribed 
medication. See appendix C. 
Specific Aims 
Specific aim #1: Identify the immediate and long-term effectiveness of comprehensive 
pelvic floor rehabilitation on women with urinary, defecatory, pelvic organ prolapse and 
pelvic pain symptoms. 
The hypotheses addressing this aim are: 
H1: Women who undergo comprehensive pelvic floor rehabilitation with an 
APRN will report ongoing improvement in urinary symptoms (via VAS) six 
months and one year following treatment. 
H2: Women who undergo comprehensive pelvic floor rehabilitation with an 
APRN will report ongoing improvement in defecatory symptoms (via VAS) six 
months and one year following treatment. 
H3: Women who undergo comprehensive pelvic floor rehabilitation with an 
APRN will report ongoing improvement in symptoms of pelvic pain (via VAS) 
six months and one year following treatment. 
H4: Women who undergo comprehensive pelvic floor rehabilitation with an 
APRN will report improved QOL (via PFDI-20 and PFIQ-7) immediately 
following treatment, in six months and one year.  
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Specific aim #2: Determine the impact of continuance of learned behavior modification 
on symptom improvement in women immediately following comprehensive pelvic floor 
rehabilitation and in six months and one year.  
The hypotheses addressing this aim are: 
H1: In women who undergo comprehensive pelvic floor therapy with an APRN, 
greater practice of daily pelvic floor muscle strengthening exercises (group #1: at 
least 4 x day compared to group #2 at least 2xday) will be associated with greater 
symptom improvement (via VAS) six and twelve months following treatment. 
H2: In women who undergo comprehensive pelvic floor rehabilitation with an 
APRN, the extent to which they continue the recommended bowel treatment 
program (group #1 compliant compared to group#2 noncompliant) will be 
associated with greater symptom improvement (via VAS) six and twelve months 
following treatment.  
Data Set  
This proposed study is a secondary analysis of a unique and robust data set. This 
data set was collected longitudinally and includes information from 406 women who 
presented for comprehensive pelvic floor rehabilitation by one of two APRNs at a 
Midwest academic outpatient urogynecology clinic for symptoms of PFD between 
February 2013 and February 2016. This secondary analysis will measure symptom 
improvement and changes in QOL of women with symptoms of PFD immediately 
following treatment, in six and twelve months. It will also attempt to determine predictor 
variables contributing to symptom improvement. 
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METHODOLOGY 
Design  
 A secondary analysis of this data set will be performed. Sample size is 406 
women who presented for comprehensive pelvic floor rehabilitation with one of two 
APRNs from February 2013 to February 2016. Data analysis will include PFDI-20 and 
PFIQ-7 questionnaires administered at baseline, completion of treatment, six months and 
one year to determine QOL changes associated with the intervention. Pelvic Floor 
Therapy Evaluation forms, which included VAS, administered at return treatment 
sessions, six months and one year will be analyzed to determine perceived improvement 
in urinary, defecatory and pelvic pain symptoms. The Evaluation form will also track 
compliance with pelvic muscle exercises and the recommended bowel treatment program 
to determine if they are associated with symptom improvement at six months and one 
year following treatment (see appendix C). This data base is ongoing and only data 
collected up to February 2016 will be analyzed for the purpose of this study.  
Proposed Study Limitations  
There are several study limitations that should be considered. Generalizability is a 
concern as only women presenting to a single Midwest academic urogynecology 
outpatient clinic are represented in this data set. Also, questionnaire and VAS data 
analysis will be performed only on those subjects who presented for therapy and returned 
for multiple subsequent visits, representing some of the most motivated patients.  Another 
limitation is that data are not available for a control group which would have 
strengthened this secondary analysis. Additionally, though all subjects received similar 
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treatment, each subject was assigned to one of two APRNs which could potentially be 
confounding because of individual provider treatment styles. It will be difficult to discern 
the effect of individual treatment modalities on subject outcomes as there were multiple 
interventions administered for each subject, however the primary outcome is the 
comprehensive management of these subjects.  
Inclusion/exclusion criteria 
Only those subjects who completed a course of treatment and returned their six 
and/or twelve month questionnaires will be analyzed. Questionnaires will not be analyzed 
on those lost to follow up; however, demographic data for all subjects will be reported.  
Data Analysis  
Table 3.1 summarizes the specific aims, hypotheses and overview of the analyses.  
Table 3.1 Specific Aims and Hypotheses 
Aims Hypothesis Measures Analysis 
1. Identify the 
immediate and 
long-term 
effectiveness of 
comprehensive 
pelvic floor 
rehabilitation on 
women with 
urinary, 
defecatory, and 
pelvic pain 
symptoms. 
H1: Women who undergo 
comprehensive pelvic floor 
rehabilitation with an 
APRN will report ongoing 
improvement in urinary 
symptoms (via VAS) 6 
months and 1 year 
following treatment. 
VAS A repeated measure ANOVA 
will be used to analyze these 
findings. If the data are not 
normally distributed, as 
assessed by a combination of 
the Shapiro-Wilk test and 
visual inspection of the 
distribution, a non-parametric 
repeated measures test such as 
the Friedman’s test will be 
applied. 
 H2: Women who undergo 
comprehensive pelvic floor 
rehabilitation with an 
APRN will report ongoing 
improvement in defecatory 
symptoms (via VAS) 6 
VAS A repeated measure ANOVA 
will be used to analyze these 
findings. If the data are not 
normally distributed, as 
assessed by a combination of 
the Shapiro-Wilk test and 
visual inspection of the 
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months and 1 year 
following treatment. 
 
distribution, a non-parametric 
repeated measures test such as 
the Friedman’s test will be 
applied. 
 H3: Women who undergo 
comprehensive pelvic floor 
rehabilitation with an 
APRN will report ongoing 
improvement in symptoms 
of pelvic pain (via VAS) 6 
months and 1 year 
following treatment. 
VAS A repeated measure ANOVA 
will be used to analyze these 
findings. If the data are not 
normally distributed, as 
assessed by a combination of 
the Shapiro-Wilk test and 
visual inspection of the 
distribution, a non-parametric 
repeated measures test such as 
the Friedman’s test will be 
applied. 
 H4: Women who undergo 
comprehensive pelvic floor 
rehabilitation with an 
APRN will report improved 
QOL (via PFDI-20 and 
PFIQ-7) immediately 
following treatment, in 6 
months and 1 year. 
PFDI-20  
PFIQ-7 
Repeated measures ANOVA 
for each outcome will be used 
to analyze this data. A non-
parametric repeated measures 
test will be applied if the data 
are not normally distributed. 
2. Determine the 
impact of 
continuance of 
learned behavior 
modification on 
symptom 
improvement in 
women 
immediately 
following 
comprehensive 
pelvic floor 
rehabilitation and 
in 6 months and 1 
year. 
H1: In women who 
undergo comprehensive 
pelvic floor therapy with an 
APRN, greater practice of 
daily pelvic floor muscle 
strengthening exercises 
(group #1: at least 4xday 
compared to group #2 at 
least 2xday) will be 
associated with greater 
symptom improvement (via 
VAS) at 6 and 12 months 
following treatment 
.  
 
VAS Analyses will be performed to 
determine distribution of the 
data. If the data is normally 
distributed, a parametric test 
such as ANOVA or Pearson’s r 
will be performed for the 
bivariate analysis. If the data 
are not normally distributed a 
nonparametric test such as 
Kruskal-Wallis or Spearman’s 
rho will be conducted.  
Continuous variables (ie. Age, 
BMI, # of vaginal deliveries) 
will be analyzed with the VAS 
using Pearson’s if normally 
distributed or Spearman’s rho if 
not normally distributed.  
Nominal variables (ie. POP, 
diabetes, history of obstetrical 
injury) will be analyzed with 
the VAS using ANOVA if 
normal distribution or Kruskal-
Wallis if not normally 
distributed.  
General linear model ANOVA 
on ranks at the three different 
time points will be analyzed to 
predict the effect of pelvic 
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muscle exercise on the VAS 
(symptom improvement) while 
adjusting for potential 
confounders.  
 H2: In women who 
undergo comprehensive 
pelvic floor rehabilitation 
with an APRN, the extent 
to which they continue the 
recommended bowel 
treatment program (group 
#1 compliant compared to 
group #2 noncompliant) 
will be associated with 
greater symptoms 
improvement (via VAS) at 
6 and 12 months following 
treatment.  
 
VAS Analyses will be performed to 
determine distribution of the 
data. If the data is normally 
distributed, a parametric test 
such as ANOVA or Pearson’s r 
will be performed for the 
bivariate analysis. If the data 
are not normally distributed a 
nonparametric test such as 
Kruskal-Wallis or Spearman’s 
rho will be conducted. 
Continuous variables (ie. Age, 
BMI, # of vaginal deliveries) 
will be analyzed with the VAS 
using Pearson’s if normally 
distributed or Spearman’s rho if 
not normally distributed.  
Nominal variables (ie. POP, 
diabetes, history of obstetrical 
injury) will be analyzed with 
the VAS using ANOVA if 
normal distribution or Kruskal-
Wallis if not normally 
distributed.  
General linear model ANOVA 
on ranks at the three different 
time points will be analyzed to 
predict the effect of compliance 
with recommended bowel 
treatment program on the VAS 
(symptom improvement) while 
adjusting for potential 
confounders. 
 
 
The first aim and hypotheses one through three are focused on symptom 
improvement which was tracked with a VAS administered on each return visit and at six 
and twelve months. Data analyzed will report perceived improvement change in urinary, 
defecatory and pelvic pain symptoms following initiation of treatment and at six and 12 
months. A repeated measure ANOVA will be used to analyze these VAS data. If the data 
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are not normally distributed, as assessed by a combination of the Shapiro-Wilk test and 
visual inspection of the distribution, a non-parametric repeated measures test such as the 
Friedman’s test will be applied. The fourth hypothesis is focused on subject change in 
QOL immediately following the intervention and six and twelve months. The PFDI-20 
and PFIQ-7 questionnaires administered at initiation and end of treatment, in six and 
twelve months will be analyzed. Repeated measures ANOVA for each outcome will be 
used to analyze this data. A non-parametric repeated measures test will be applied if the 
data are not normally distributed. 
The second specific aim and hypotheses seek to determine the impact of 
continuance of learned behavior modification on symptom improvement via VAS in 
women six months and one year following treatment end. Data collected on the Pelvic 
Floor Therapy Evaluation forms administered at the second through final treatment and at 
six and twelve months will be entered and analyzed, specifically the number of times a 
day per day a subject performs pelvic muscle exercises and compliance with the 
recommended bowel treatment program.  
Data for the first hypothesis will be divided into two groups. Group #1: performs 
pelvic strengthening exercises at least 4 x day and group #2: performs pelvic 
strengthening exercises at least 2 x day. Analyses will be performed to determine 
distribution of the data. If the data are normally distributed, a parametric test such as 
ANOVA or Pearson’s r will be performed for the bivariate analysis. If the data are not 
normally distributed a nonparametric test such as Kruskal-Wallis or Spearman’s rho will 
be conducted.  Continuous variables (ie. Age, BMI, # of vaginal delivers, # of sessions 
completed) will be analyzed with the VAS using Pearson’s if normally distributed or 
 
 
49 
 
Spearman’s rho if not normally distributed.  Nominal variables (ie. POP, diabetes, history 
of obstetrical injury) will be analyzed with the VAS using ANOVA if normal distribution 
or Kruskal-Wallis if the data are not normally distributed. General Linear Models 
ANOVA on ranks at the three different time points will be analyzed to predict the effect 
of pelvic muscle strengthening exercise on the VAS (perceived symptom improvement) 
while adjusting for potential confounders. 
Data for the second hypothesis will be divided into two groups. Group #1: 
compliance with the recommended bowel treatment program and group #2: noncompliant 
with the recommended bowel treatment program.  Analyses will be performed to 
determine distribution of the data. If the data is normally distributed, a parametric test 
such as ANOVA or Pearson’s r will be performed for the bivariate analysis. If the data 
are not normally distributed a nonparametric test such as Kruskal-Wallis or Spearman’s 
rho will be conducted.  Continuous variables (ie. Age, BMI, # of vaginal deliveries, # of 
sessions completed) will be analyzed with the VAS using Pearson’s if normally 
distributed or Spearman’s rho if not normally distributed.  Nominal variables (ie. POP, 
diabetes, history of obstetrical injury) will be analyzed with the VAS using ANOVA if 
the data are normally distributed or Kruskal-Wallis if not normally distributed. General 
linear model ANOVA on ranks at the three different time points will be analyzed to predict 
the effect of bowel treatment compliance with VAS (perceived symptom improvement) 
while adjusting for potential confounders (NCSS 11 Kaysville, Utah). 
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CHAPTER FOUR 
Manuscript: Outcomes of Comprehensive Management of Pelvic Floor  
Dysfunction in Women: A Secondary Analysis 
 
Title 
Outcomes of Comprehensive Management of Pelvic Floor  
Dysfunction in Women: A Secondary Analysis 
 
Abstract 
Objective: Traditional management of pelvic floor dysfunction (PFD) in women has 
followed a clinically compartmentalized and fragmented approach, potentially failing to 
address multiple etiologies, frequently resulting in incomplete resolution of symptoms. 
Women with symptomatic PFD often consult with many different health care providers, 
increasing the potential for duplication and delay in treatment. Multiple referrals can 
result in increased cost of care and decreased patient satisfaction. Advanced Practice 
Nurses in a urogynecology clinic are uniquely positioned to provide comprehensive care 
to women with urinary, defecatory and pelvic pain complaints. The aim of this secondary 
analysis was to determine immediate and long-term symptom improvement and change 
in quality of life (QOL) in women with symptoms of PFD who underwent a course of 
comprehensive pelvic floor rehabilitation with an APRN at an outpatient academic 
urogynecology clinic.  
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Methods: This study is a secondary analysis of a prospective data set of women who 
underwent treatment for symptoms of PFD by an APRN between February 2013 and 
February 2016. Data were analyzed on subjects who completed up to five 30 to 45-
minute treatment sessions with an APRN which included pelvic muscle biofeedback; 
vaginal electrogalvanic stimulation; behavior modification; and in some cases pessary 
fitting or pharmacologic intervention. Data collected included, but was not limited to, 
validated QOL instruments at baseline (e.g. PFDI-20 and PFIQ-7) and subject perception 
of symptom improvement as measured by visual analog scale (VAS) at following 
initiation of treatment; and six and twelve months following treatment completion.  
Results: Four hundred twenty-eight subjects were enrolled in the initial database. Data 
were considered sufficient for analysis among 406 subjects with data available from the 
initial visit. Demographic data revealed a median age of 51 and median parity of two. 
Ninety-seven percent were Caucasian and 48% reported a history of third or fourth 
degree obstetrical injury. Subjects experienced a statistically significant improvement in 
QOL, which was durable at one year. VAS results revealed 80% median perceived 
improvement in urinary, defecatory, and pain symptoms six and 12 months following 
treatment. There was insufficient data to determine if compliance with pelvic muscle 
exercises and constipation management affected symptom improvement12 months 
following completion of treatment.  
Conclusion: This secondary analysis suggests that comprehensive pelvic floor 
rehabilitation for women with symptoms of PFD by an APRN is efficacious and results in 
improved QOL which is durable to one year.  
 
 
52 
 
Introduction 
Pelvic floor dysfunction (PFD) comprises symptoms associated with anatomical 
and functional disturbances of the lower urinary tract and micturition; lower 
gastrointestinal tract and defecation; and sexual function and/or pelvic pain (Delancey, 
2005; Morgan, Delancey, Guire, & Fenner, 2007). These symptoms can range from 
bothersome to debilitating and are challenging to patients and professionals in both 
primary and specialty care settings. The cost of managing PFD is ever increasing due to 
rising public expectations of health care, technological advances and increasing 
prevalence of predisposing factors such as diabetes, obesity and an aging population. 
Demand for care associated with PFD is predicted to rise by 50% over the next 30 years, 
resulting in increased health care cost and Medicare spending (Luber, Boero, & Choe, 
2001).  
Symptoms of PFD are common among women of all ages with increasing 
prevalence in middle aged and older populations. The risk of developing symptoms is 
estimated at 40% of women between 65 and 70 years and increases to 50% in those over 
80 (Nygaard, Barber, Burgio, 2008). It is estimated that 11% of women will undergo 
surgical intervention for PFD and 30% will return to surgery as a result of symptom 
recurrence (Olsen, Smith, Bergstrom, Colling, Clark, 1997).        
Pelvic floor disorders often coexist and it is estimated that 23.7% of women have 
one or more pelvic floor disorders (Nygaard et al., 2008).  As the population ages, health 
care utilization for PFD is predicted to grow. Wu and colleagues (2010) used US Census 
Bureau population projections to estimate the total number of women who will undergo 
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surgery for pelvic organ prolapse from 2010 to 2050 and determined that this number is 
expected to increase by 48.2% over these four decades. 
The limitation of studies on health care utilization is that some women with PFD 
do not seek care. In a population-based sample of women 40 years or older, the 
prevalence of UI was 41%; but only 25% of symptomatic women sought care, 23% 
received some care, and 12% received subspecialty care (Minassian et al., 2012).  In a 
community-based Internet survey of women older than 45 years, 19% reported accidental 
bowel leakage but only 29% of those had sought care (Brown, Wexner, & Lukacz, 2013). 
Thus, the incidence of care seeking provides an underestimate of the public health burden 
of PFD among US women. 
PFD is a multidisciplinary issue and traditional management has followed a 
clinically compartmentalized and fragmented approach, potentially failing to address 
multicompartmental symptomology resulting in incomplete resolution of the problem 
(Davis, Kumar, & Wake 2010). Women with PFD often consult with many different 
health care providers, increasing the potential for duplication and delay in treatment. 
Patients presenting to their primary care physician with urinary complaints are often 
referred to a urologist. Those with defecatory symptoms are historically treated by a 
gastroenterologist or a colorectal surgeon and women with pelvic and/or sexual pain are 
most often referred to gynecology for evaluation and management. Multiple referrals 
contribute to increased health care costs and patient frustration with care. 
A more standardized comprehensive approach in managing PFD as a single 
clinical entity would be beneficial to women and potentially decrease cost associated with 
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managing the multitude of symptoms associated with PFD. There is considerable 
evidence supporting the clinical and cost-effectiveness of nurse specialists in the 
management of urinary incontinence. Advanced practice nurses (APRNs) and Physician 
Assistants practicing in urology and urogynecology settings are especially qualified to 
comprehensively manage women with PFD (Newman & Wein, 2013). They are licensed 
to perform detailed history and physicals, counsel women on behavior modification 
including pelvic muscle exercise training, prescribe medication, and fit and manage 
pessaries if indicated. They often have the luxury of arranging for longer appointment 
times compared to medical consultations. This ability to nonsurgically manage the 
multitude of etiologies and symptoms associated with PFD can potentially result in more 
unified, comprehensive, cost effective care and improved patient satisfaction.  
In 2013 this researcher published a retrospective review of 728 women with 
symptoms of PFD who underwent comprehensive pelvic floor rehabilitation by an APRN 
in a Midwest Academic female pelvic medicine and reconstructive surgery clinic. 
Treatment included a conglomeration of pelvic floor muscle training (PFMT), 
biofeedback, behavior modification, electrogalvanic stimulation (EGS), incontinence 
devices and various indicated pharmacotherapies. These patients reported a mean 
symptom improvement of 80-85% in urinary, defecatory and pelvic pain symptoms after 
five treatment sessions (Starr et al., 2013). These outcomes are significant, but the 
women were not prospectively enrolled and were not followed longitudinally after 
treatment. Several questions remained unanswered including: 1) “How effective is 
comprehensive management of PFD by an APRN over time?”  2) “If symptom control is 
maintained, what variables predict symptom stability?”   
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The current study is a secondary analysis of a prospective database of women 
who were referred to these same APRNs for comprehensive treatment of PFD. Validated 
questionnaires were distributed and demographic data were collected. The subjects were 
followed for up to one year after completion of treatment in an attempt to gain insight, 
into the complex management of PFD by an APRN and make a scientific contribution to 
the literature for non-surgical management of women with these life altering symptoms. 
Materials and Methods 
Study Overview 
This secondary analysis of a prospective database was approved by the University 
of Missouri Health Sciences IRB in 2016. All women >18 years of age who presented to 
this academic outpatient female pelvic medicine and reconstructive surgery practice for 
comprehensive pelvic floor rehabilitation by an APRN between February 2013 and 
February 2016 were asked to enroll in the database at the initial visit. There was no 
incentive offered and the number of subjects that declined to participate or did not return 
for treatment was recorded. The subjects were scheduled for a total of five 
visits/appointments with the APRN, either weekly or every other week, depending on 
financial or time constraints, transportation issues and symptom severity. Those with a 
primary complaint of pelvic pain were recommended to return weekly for optimal 
symptom management. Patients who lived a distance from the clinic were offered the 
option of renting a Pathway STM-10 portable battery-operated EGS device (Prometheus, 
Dover NH) to perform treatments at home. Two validated QOL questionnaires, Pelvic 
Floor Distress Inventory-20 (PFDI-20) and Pelvic Floor Impact Questionnaire-7 (PFIQ-
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7) (Barber et al., 2011) (see appendix A&B) were completed at the first and last treatment 
session and mailed to the subjects six and twelve months after treatment completion. 
Visual analog scales (VAS) were used to track changes in subject global impression of 
symptom improvement at each successive treatment and at six and twelve months. Pelvic 
Floor Therapy Evaluation Forms (see appendix C) were completed to track subject 
symptoms and compliance with recommended behavioral therapies such as pelvic muscle 
exercises and the recommended bowel regimen. Data were analyzed on 406 subjects who 
completed treatment and were mailed a questionnaire six and 12 month post treatment. 
Of those 406 subjects 196 completed at least three treatment sessions and completed the 
VAS and/or PFDI-20 and PFIQ-7 at end treatment. Demographic data were analyzed on 
all 406 subjects.  
Intervention 
APRNs Role 
Comprehensive pelvic floor rehabilitation was performed by one of two APRNs 
at this Midwest female pelvic medicine and reconstructive surgery outpatient clinic. The 
APRNs are board certified family nurse practitioners with a combined experience of 30 
years in urology and/or urogynecology and have each been managing women with 
symptoms of PFD in this clinic for at least eight years. Subjects were directly referred to 
either of the APRNs by one of two collaborating board certified urogynecologists within 
the clinic. Outside referrals were common among family practice, gynecology, urology, 
colorectal and gastroenterology providers. Common referring diagnoses included stress 
urinary incontinence, urinary urgency/frequency, urgency incontinence, nocturia, voiding 
 
 
57 
 
dysfunction, incomplete bladder emptying, outlet obstruction defecation, pelvic pain, 
dyspareunia, hypertonic pelvic floor muscles, pelvic organ prolapse and pelvic muscle 
weakness.  
Comprehensive History and Genitourinary Exam 
The first appointment with the APRN included a complete history and physical 
with a focus on presenting pelvic floor symptoms. The subject was asked to empty her 
bladder and a lower abdominal and pelvic exam was performed. Visual examination of 
the mons, vulva and perineum was completed to assess for skin abnormalities such as 
abnormal lesions, lichens sclerosis or dermatitis. A vulvar workup was completed (ie: Q-
tip test, vaginal pH, wet prep and fungal culture) if symptoms of dyspareunia and/or 
pelvic pain were reported. A 14 French non-dwelling urinary catheter was inserted into 
the urethra to drain the bladder and measure post void residual if urinary symptoms were 
reported. Office urinalysis was performed and the specimen was sent for culture if 
positive for leukocytes, nitrites or blood. Pelvic organ prolapse quantification (Bump et 
al., 1996) scoring was performed to determine support of the apical, anterior and 
posterior vaginal compartments. Split speculum examination was performed to assess for 
vaginal tissue atrophy and abnormal lesions. Digital examination of the levator ani 
muscles was performed to assess for tone and painful trigger point areas. The subject was 
asked to perform a pelvic muscle contraction to assess for strength and proper isolation of 
this muscle group. A rectal exam was then completed to assess for anal tone and perineal 
support as well as any abnormal findings such as hemorrhoids, fissures or anal/rectal 
mass.  
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Biofeedback 
Biofeedback of the pelvic floor was then performed with use of the Prometheus 
CTS 2000 (Prometheus, Dover NH). The subject was assisted into a comfortable semi-
recumbant position with the HOB elevated 20-30 degrees. An abdominal EMG patch was 
placed on the rectus abdominus muscle just below the umbilicus to monitor accessory 
muscle during PFM contraction. A vaginal probe was inserted to monitor PFM EMG and 
in some cases a 3cm manometry probe filled with 1.5cc of air was placed in the anal 
canal to measure PFM strength and endurance. The subject was able to view the monitor 
which showed all 3 modalities simultaneously (see figure 2). PFM resting tone was 
measured by having the subject completely relax for 30 seconds.  They were then given 
verbal cues by the APRN to contract and relax their pelvic floor. Ten, 10 second 
contraction with 10 second relaxation periods were performed to assess for PFM strength, 
endurance, fatigue, and change in resting tone. The rectal probe and abdominal patch 
were then removed. Proper placement of the vaginal probe was confirmed then two 
pillows were placed under the subjects knees and the legs were extended so that the 
subject was able to relax.  
Vaginal EGS 
Vaginal EGS therapy was then performed for 30 minutes. The APRN chose a 
frequency and intermittent or constant delivery based on the patients symptoms and 
initial resting tone. A constant setting was used if the patients PFM resting tone measured 
>4 microvolts, otherwise an intermittent stimulation was delivered 5 seconds on and 5 
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seconds off.  During the treatment time the amplitude was adjusted by the APRN so that 
the subject sensed a strong yet not uncomfortable sensation.  
Patient Education/Behavior Modification 
Patient education was conducted by the APRN while the subject was undergoing 
EGS therapy. Pictures of the PFMs and pelvic organs were used to enhance 
understanding of symptoms. A specific PFM exercise regimen was prescribed based on 
the individuals PFM strength and endurance. Patients with symptoms of pelvic pain 
and/or dyspareunia were instructed on PFM relaxation exercises and pelvic stretches. 
Sitting on a heating pad was recommended twice a day for 20 minutes to help relax the 
PFMs. Subjects with symptoms of urinary urgency and frequency and/or nocturia were 
instructed on urge suppression techniques and timed voiding. They were also given a list 
of foods and beverages that could potentially contribute to their urgency symptoms. Fluid 
intake was discussed. It was recommended that 64oz of non-caffeinated beverages be 
consumed daily. Obese women were counseled on weight loss and referred to the 
bariatric center if they were interested in a formalized weight loss program. Smoking 
cessation was also addressed. A bowel regimen including daily use of psyllium fiber and 
as needed magnesium hydroxide was recommended to facilitate complete emptying of 
the rectum every morning. As needed use of loperamide was advised for those with 
symptoms of loose stools, rectal urgency, and/or fecal incontinence. Appropriate teaching 
handouts were provided for the subject to review at home. 
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Additional Treatment Options 
Each visit with the APRN included biofeedback, EGS, behavior modification 
reinforcement and if indicated constipation management.  It was recommended that the 
patients return every 1-2 weeks for a total of five treatments. If they continued to be 
bothered by their symptoms after five sessions, other treatment options were offered such 
as pessary fitting for prolapse or stress urinary incontinence; or medication for remaining 
symptoms of over-active-bladder. Surgical intervention was an option for women who 
continued to be bothered by prolapse. Those with stress urinary incontinence who did not 
desire a pessary were offered placement of a midurethral sling. Those with refractory 
overactive bladder, incomplete bladder emptying or fecal incontinence were candidates 
for a trial of sacral neuromodulation.  
Medications were sometimes prescribed. Subjects with urogenital atrophy were 
prescribed Premarin vaginal cream or their current estrogen cream was adjusted at the 
initial visit. Those still experiencing nocturia after their fourth treatment were offered 
imipramine 25mg or melatonin at bedtime though this was rarely necessary. Nocturnal 
polyuria was ruled out with a patient bladder diary. Those with overactive bladder were 
offered oxybutynin 5mg tid prn if they did not desire to take a daily medication for 
symptom control and were not responding to the treatment which was uncommon. If an 
antimuscarinic was desired, the patients’ insurance plan often influenced the medication 
prescribed. Solifenacin or mirabegron were often a first choice if affordable.  
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Results 
Data were gathered on 406 women between February 2013 and February 2016. 
Demographic data revealed a mean age of 51 and body mass index of 29. Most subjects 
had completed some college education. Median gravity and parity was two with 
predominantly vaginal deliveries. The number of treatment sessions attended ranged from 
one to eight with an average total of three. A majority of subjects were Caucasian 
menopausal women with equal distribution of stage 0-II pelvic organ prolapse. It is worth 
noting that 50% of those enrolled reported a history of a third or fourth degree obstetrical 
laceration with delivery. A majority were sexually active (71%) with 49% reporting 
painful intercourse. Patient characteristics are shown in Table 4.1&4.2.  
Table 4.1. Numerical Demographic Data (n=406) 
Measure Median Range 
Age 51 18 - 88 
BMI 29 17 - 40 
Education (years) 14 4 - 20 
Gravidity 2 0 - 11 
Parity 2 0 - 11 
Vaginal deliveries 2 0 - 7 
C-section deliveries 0 0 - 4 
Term Pregnancies 2 0 - 8 
Total Sessions of PFT 3 1 - 8 
Urinary pads per day 1 0 - 25 
Urinations per day 2 1 - 9 
Leaks per day 1 0 - constant 
Urinations at night 1.5 0 - 9 
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Table 4.2.  Categorical Demographic Data (n=406) 
 
Pelvic Floor Therapy Evaluation forms, which included the VAS were collected 
from the second through the final visit and at six and 12 months following treatment 
completion to track changes in bladder, bowel and pelvic pain symptoms. Data collected 
on the evaluation form included but were not limited to subject perceived global 
improvement in symptoms via VAS, urinary symptoms, nocturia, pad use, pain scores 
and frequency of bowel movements (appendix C). Because the VAS measures subject 
Measure Percent 
Incontinence surgery 12 
Other pelvic surgery 48 
Smoker 10 
Ever a smoker 25 
Obstetrical Laceration- 
3
rd
 or 4
th
 degree 
50 
Sexually active 71 
Diagnosis of stress incontinence 82 
Diagnosis of urge incontinence 22 
Diagnosis of mixed incontinence 54 
Diagnosis of fecal incontinence 18 
Diagnosis of pelvic muscle spasm 76 
Diagnosis of defecatory dysfunction 71 
Diagnosis of pelvic pain 30 
Diagnosis of vaginal pain 5 
Diagnosis of dyspareunia 49 
Wears pads 56 
Bladder empty post void 32 
Medication-narcotic 8 
Medication-anticholinergic 11 
Medication-diuretic 14 
Oral contraceptive 12 
Hormone replacement therapy 9 
Vaginal estrogen 48 
Measure Group Percent 
 Race Caucasian 97 
Marital Status Single 20 
Married 63 
Widowed 9 
Divorced 6 
Separated 2 
Employment Employed 61 
Unemployed 5 
Student 2 
Home Parent 6 
Retired 19 
Disabled 6 
Menopause 
status 
Pre- 45 
Peri- 5 
Post- 37 
Surgical 13 
Pelvic Organ 
Prolapse (POP) 
stage 
0 34 
1 32 
2 29 
3 4 
Hysterectomy   40 
Prolapse repair   11 
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perceived symptom improvement, they were administered with each return visit 
following initiation of treatment and six and 12 months following treatment. See tables 
4.3, 4.4 & 4.5. The data for this analysis were not normally distributed by Shapiro-Wilk 
test or visual inspection. Friedman’s test (non-parametric, repeated measures) was used to 
detect significant differences between the VAS score after the final treatment and 6- and 
12-month VAS scores; no differences were found, indicating the treatment effect was 
sustained through 12 months. Subjects reported 80% median improvement in symptoms 
at end treatment via VAS and no decline was noted at 6 and 12 months. (Figures 4.1-4.3). 
Table 4.3. Percent in Urinary Symptom Improvement by VAS 
n Final 6 months 12 months p 
196 80 (75 – 80)    
46 81 (40 – 85) 80 (74 – 85)  0.50 
24 84 (75 – 90)  83 (65 – 90) 0.51 
8 81 (50 – 95) 80 (50 – 90) 80 (10 – 90) 0.41 
Values are medians (95% CI). p values evaluate for differences between Final visit, 6 month and 12   
month time points by Friedman’s test for repeated measures. 
 
Table 4.4. Percent in Defecatory Symptom Improvement by VAS 
n Final 6 months 12 months p 
196 80 (75 – 80)    
37 80 (70 – 90) 80 (66 – 90)  1.0 
19 90 (70 – 99)  76 (57 – 90) 0.033 
3 70 60 86 0.37 
Values are medians (95% CI). p values evaluate for differences between Final visit, 6 month and 12    
month time points by Friedman’s test for repeated measures. 
 
Table 4.5. Percent in Pelvic Pain Symptom Improvement by VAS 
n Final 6 months 12 months p 
196 80 (75 – 80)    
16 75 (60 – 90) 77 (50 – 98)  0.59 
9   80 (50 – 100)  92 (43 – 100) 0.41 
1 90 100 100  
Values are medians (95% CI). p values evaluate for differences between Final visit, 6 month and 12   
month time points by Friedman’s test for repeated measures. 
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Figure 4.1.  Subject Reported Percentage Urinary Symptom Improvement (VAS)
Figure 4.2.  Subject Reported Percentage Defecatory Symptom Improvement (VAS) 
Figure 4.3.  Subject Reported Percentage Pelvic Pain Symptom Improvement (VAS) 
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Of the 406 women who enrolled in the study, 196 completed at least three 
treatment sessions and one or more of the questionnaires at beginning and end of 
treatment. Outcomes were significant for improvement in QOL (via PFDI-20 & PFIQ-7) 
at treatment end and sustained for up to one year. Statistical analysis revealed the results 
were not normally distributed by Shapiro-Wilk test or visual inspection; therefore, 
Friedman’s test (non-parametric, repeated measures) was used to detect significance 
(NCSS 11 Kaysville, Utah). Due to missing data at various time points, data were 
analyzed separately for subjects completing questionnaires. (Tables 4.6, 4.7, 4.8, 4.9) 
Table 4.6. QOL Improvement Final Treatment  
Outcome n Initial Final p 
PFDI-20 153 92 (81 – 102) 38 (31 – 44) 0.000 
PFIQ-7 147 38 (33 – 48) 14 (9.5 – 19) 0.000 
Values are medians (95% CI) 
p values evaluate for differences between Initial and Final visits by Friedman’s test  
 
Table 4.7. QOL Improvement Final Treatment & 6 Months  
Outcome n Initial 6 Months p 
PFDI-20 100 93 (79 – 104) 43 (37 – 55) 0.000 
PFIQ-7 89 43 (33 –57) 14 (9.5 – 24) 0.000 
Values are medians (95% CI) 
p values evaluate for differences between Initial and Final visits by Friedman’s test 
 
Table 4.8. QOL Improvement Final Treatment & 12 Months  
Outcome n Initial 12 Months p 
PFDI-20 37 92 (73 – 104) 40 (26 –66) 0.001 
PFIQ-7 37 38 (33 – 48) 4.8 (0 – 14) 0.001 
Values are medians (95% CI) 
p values evaluate for differences between Initial and Final visits by Friedman’s test 
 
Table 4.9. QOL Improvement at All Time Points  
Outcome n Initial Final 6 months 12 months p 
PFDI-20 28 88 (67 – 96) 27 (18 – 33) 42 (21 – 54) 31 (13 – 52) 0.000 
PFIQ-7 27 38 (19 – 52) 9.5 (0 – 19) 14 (0  – 14) 4.8 (0 – 9.5) 0.001 
Values are medians (95% CI)           
p values evaluate for differences between Final visit, 6 month and 12 month time points by Friedman’s 
test  
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 Data were also collected to determine if compliance with pelvic floor muscle 
exercises and compliance with the recommended bowel treatment program affected 
patient perceived symptom improvement via the VAS. General linear model ANOVA on 
ranks was used to analyze these data. No relationship was detected between frequency of 
exercises and reported symptom improvement via VAS for urinary, defecatory and pelvic 
pain symptoms at end of treatment. See table 4.10. Data analysis revealed no relationship 
detected between compliance with the recommended bowel treatment program and 
reported symptom improvement via the VAS for urinary, defecatory and pelvic pain 
symptoms at end treatment. See table 4.11. Unfortunately, a large percentage of subjects 
neglected to provide information on daily exercise frequency and compliance with the 
bowel treatment program when completing the mailed questionnaires. General linear 
model ANOVA on ranks was used analyze this small data set and no relationship could 
be determined at the six and 12 month time points.  
Table 4.10. End of Treatment Exercise Frequency-Symptom Improvement via VAS  
Exercises 
per day 
n 
Urinary  
Symptom Index 
n Defecatory  
Symptom Index 
n Pelvic Pain 
Symptom Index 
0-2 19 88 (65 – 100) 15 85 (50 – 99) 9 75 (40 – 96) 
2-4 96 80 (75 – 85) 84 86 (80 – 90) 36 85 (80 – 92) 
> 4 54 77 (70 – 80) 35 90 (80 – 100) 19 90 (70 – 95) 
p 0.73 0.48 0.86 
Values are medians (95% CI). p values are from general linear model ANOVA on ranks 
 
Table 4.11. End of Treatment Bowel Program Compliance-Symptom Improvement VAS 
Bowel Program n USI n DSI n PPSI 
YES 91 80 (75-82) 90 85 (80 – 90) 9 75 (40 – 96) 
NO 8 62 (30-95) 7 70 (19 – 100) 36 85 (80 – 92) 
p 0.73 0.48 0.86 
Values are medians (95% CI). p values are from general linear models ANOVA on ranks 
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In summary, subjects with symptoms of PFD who completed at least three 
sessions of CPFR with an APRN experienced statistically significant improvement in 
QOL, which was durable at one year. Patient perceived symptom improvement via the 
VAS revealed 80% median improvement in urinary, defecatory, and pain symptoms at 
the conclusion of treatment which was also durable for up to one year. The data showed 
significant improvements in symptoms determined by negative Spearman rank 
correlations (rs) for nocturia at final treatment (rs = -0.49, p=0.013) and at one year (rs = -
0.29, p=0.012); for urinary frequency at final treatment (rs = -0.49, p=0.009) and one year 
(rs = -0.49; p=0.0001);  for number of daily urinary incontinence incidences at final 
treatment (rs = -0.56, p=0.003) and at one year (rs = -0.56, p=0.003) and pads used per 
day at final treatment (rs = -0.71, p=0.0001) and one year (rs = -0.71, p=0.0001). To our 
knowledge, this information has not yet been reported in the literature.   
Discussion 
 The results of this secondary analysis indicate that women with symptoms of PFD 
can achieve improvement in QOL for up to one year with 3-5 sessions of CPFR by an 
APRN. This study is unique in that only women were recruited and followed for up to 
one year tracking QOL data on urinary, defecatory and pelvic pain symptoms. Previous 
research has primarily focused on the use of physical therapy administered by a physical 
therapist or physiotherapist which includes but is not limited to pelvic floor muscle 
training (PFMT) and biofeedback to treat urinary and fecal incontinence (Barroso, 
Ramos, Martins-Costa, Sanches, & Muller, 2004; Bendana et al., 2009; Dumoulin & 
Hay-Smith, 2010; Hay-Smith, Herderschee, Dumoulin, & Herbison, 2012; Norton & 
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Cody, 2012; Rai, Cody, Alhasso, & Stewart, 2012). None of these researchers followed 
subjects after completion of treatment. 
Patients with symptoms of urinary urgency, frequency and/or incontinence who 
present to their healthcare provider have historically been offered behavior modification 
and medication management. The study findings reveal that other interventions such as 
electrogalvanic stimulation (EGS) therapy and behavior modification can achieve similar 
if not better outcomes without the added cost and unpleasant side-effects associated with 
over active bladder medications. Subjects with symptoms of stress urinary incontinence 
achieved significant improvement in QOL at both end treatment and up to one year. 
Treatment options for this group of women most often include urethral bulking 
procedures which must often be repeated every 6 months, pessary fitting/management or 
surgical intervention with a mesh sling.                                     
One very significant finding of this secondary analysis is the significant 
improvement in nocturia at end treatment and for up to one year, which was tracked via 
the Pelvic Floor Therapy Evaluation form. Nocturia is defined as getting up more than 
once in the night to void and is considered clinically meaningful if a patient voids two or 
more times nightly. Nocturia is a source of significant bother and is a leading cause of 
sleep disturbance. It is associated with increased rates of depression, work absenteeism, 
congestive heart failure, and increased mortality (Dani et al., 2016; Miller et al., 2016). In 
the elderly, it is associated with increased rates of falls and fractures (Solimen et al., 
2016).  The guidelines for treatment for nocturia currently recommend behavior 
modification such as limiting fluids 2 hours before bedtime or taking a diuretic 6 hours 
prior to bedtime, rather than in the a.m. Medications for nocturia such as imipramine are 
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often associated with unpleasant side effects such as constipation, dry mouth, dry eyes 
and sometimes dizziness. Improvement in nighttime frequency was often noted after 1-2 
sessions of therapy and these subjects were thrilled to be getting adequate sleep after 
many years of getting up two or more times in the night to void.  
Patients with symptoms of constipation are historically treated with stimulant 
laxatives which can cause harm to the small intestine and colon with long term use. These 
study findings lend evidence to the possibility of another successful treatment option 
based on behavior modification and EGS therapy. A majority of subjects were using 
nothing more than a bulk forming laxative such as psyllium fiber at end treatment to 
achieve almost daily bowel movements without straining. The majority of subjects with 
symptoms of fecal incontinence responded to daily use of a bulk forming laxative and prn 
use of loperamide. Those that did not respond to this regimen were referred for a trial of 
sacral neuromodulation.  
To date, when women with bothersome symptoms of pelvic organ prolapse 
present to their health care provider, they are given three options: 1) do nothing 2) 
pessary fitting or 3) surgical intervention. However, subjects with stage II or less prolapse 
(i.e. prolapse that does not extend more than 2 cm outside of the hymenal ring) reported 
significant improvement in their prolapse symptoms with EGS treatment, constipation 
management and daily pelvic floor strengthening exercises. Being able to offer women 
something other than pessary or surgery has not been reported in the literature.  
Another interesting finding is the percentage of subjects who presented for 
treatment with a history of a third or fourth degree obstetrical injury during childbirth.  Of 
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those presenting for treatment, 50% had undergone previous vaginal delivery with injury 
to the anal sphincter. These findings suggest that women with the aforementioned injuries 
are at increased risk of symptoms of PFD and beg the question: Would these women 
benefit from comprehensive pelvic floor rehabilitation soon after delivery to decrease 
their risk of developing future symptoms of PFD?  
Though these findings are impressive, there are several limitations to this study. 
Ninety-seven percent of the subjects were white and presented for repeated treatments at 
a single institution, limiting the generalizability of the results. Also, many subjects were 
lost to follow up, especially at the 12-month time point. Though the research staff was 
diligent in mailing the questionnaires and attempting to follow up via phone call, it was 
difficult to contact over 50% of the subjects following treatment. Also, many of the 
subjects did not complete the section of the mailed questionnaire asking average number 
of times a day they performed pelvic muscle exercises making it difficult to discern if 
compliance with the exercises affected long term symptom stability. Compliance with the 
bowel regimen was also difficult to track after end treatment; therefore, constipation 
management as a contributing factor to ongoing symptoms stability is also unclear. Most 
importantly, because this design lacks a control group, one can only conclude that there is 
a statistical correlation/association between the treatment and the reported outcome.  
This researcher has spent the past nine years talking to and treating women with 
symptoms of PFD. Women desire more than just medication or surgical options for these 
life-altering symptoms. Many yearn for information about the possible causes of their 
symptoms and want to be actively involved in making life-style changes for better 
symptom management. Having contact with an APRN over a six to10-week time period 
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provides an opportunity to focus on this complex conglomeration of symptoms and assist 
the patient in understanding their diagnoses and treatment plan. Women often make the 
statement at their last visit that they have, “learned so much about my pelvic floor” as 
they are given the tools to manage their symptoms over time. Many share their success 
with friends and family members, leading to self-referrals to the clinic as well as 
increasing number of referrals from other healthcare providers.  
Ongoing research is needed to add to the paucity of literature surrounding non-
surgical management of PFD in women. These study findings reveal that comprehensive 
pelvic floor rehabilitation by an APRN improves QOL at end treatment and for up to one 
year. While not all the hypotheses were supported, the findings provide valuable 
information about long term management of symptoms of PFD and inspired ideas for 
ongoing research. Future randomized controlled trials are being designed to determine the 
efficacy of EGS therapy alone as it is thought to be a huge contributor to treatment 
success and there is little published scientific data regarding the specifics of EGS. 
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CHAPTER FIVE 
Conclusion 
Summary 
There is a paucity of literature evaluating the aggregate clinical effect of 
comprehensive, multimodal nonsurgical pelvic floor rehabilitation. Current research is 
primarily focused on the use of physical therapy administered by a physical therapist or 
physiotherapist which includes but is not limited to pelvic floor muscle training (PFMT) 
and biofeedback to treat urinary and fecal incontinence (Barroso, Ramos, Martins-Costa, 
Sanches, & Muller, 2004; Bendana et al., 2009; Dumoulin & Hay-Smith, 2010; Hay-
Smith, Herderschee, Dumoulin, & Herbison, 2012; Norton & Cody, 2012; Rai, Cody, 
Alhasso, & Stewart, 2012). The improvement in symptoms afforded by mono modal 
PFMT is modest, with approximately 43% reported improvement in outpatient non-group 
therapy (Hay-Smith et al., 2012).  
The retrospective findings reported by Starr et al., (2013) was the first to report 
significant symptom improvement following comprehensive pelvic floor rehabilitation by 
an APRN. The data suggested that women who completed three to five sessions, which 
included pelvic floor muscle training, biofeedback, behavior modification, EGS and 
sometimes incontinence devices and pharmacotherapies reported a median improvement 
of 80% in urinary, defecatory and pelvic pain symptoms.  The recent secondary analysis 
reproduced these findings in its report of 80% median symptom improvement sustained at 
6 and 12 months. In addition to the retrospective study, the prospective results were 
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supported by validated questionnaires which revealed significant improvement in QOL at 
end treatment which was sustainable for up to one year.  
Significance 
Traditional management of PFD in women has followed a clinically 
compartmentalized and fragmented approach, potentially failing to address 
multicompartmental symptomology resulting in incomplete resolution of the problem. 
Women with symptoms PFD often consult with many different health care providers, 
increasing the potential for duplication and delay in treatment. Multiple referrals can 
result in increased cost of care and decreased patient satisfaction. Because coexisting 
pelvic floor disorders are common, evaluation and management of all pelvic floor 
symptoms by a health care provider specializing in the treatment of PFD could improve 
overall outcomes for women.  APRNs in a urogynecology clinic are uniquely positioned 
to provide comprehensive care to women with urinary, defecatory and pelvic pain 
complaints. The research findings have served to advance the science of comprehensive 
nonsurgical management of symptoms of PFD by an APRN, resulting in improved QOL 
for women with these life altering symptoms.  
A successful comprehensive pelvic floor rehabilitation program is dependent on a 
number of factors including patient recruitment, clearly defined expectations of treatment 
outcomes and cost, well-educated and motivated staff, proper billing, coding and 
reimbursement, and ongoing efforts to maintain compliance in patients returning for 
treatment. Early on in practice, the researcher contacted referring providers and their staff, 
informing them of the benefit of this type of treatment plan for women with symptoms of 
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PFD and the population of patients that would benefit from this program. The program was 
promoted at local family practice clinics, OB/GYN clinics, independent/assisted living 
facilities, fitness centers, and health fairs. Additionally, a multitude of self-referrals were 
made from friends of women who successfully completed the program. It is likely that one 
of the biggest reasons for treatment success was the APRNs providing the treatment. They 
are equipped to address a diversity of pelvic floor health needs that could not be 
immediately addressed by a physical therapist or physiologist. For example, patients with 
urogenital atrophy could be prescribed vaginal estrogen, patients with levator spasm could 
be prescribed muscle relaxants, and patients with pelvic organ prolapse could be fit with 
pessaries. Although anticholinergic medications could be prescribed this was rarely 
required. Additionally, the APRNs were trained to administer biofeedback and EGS 
therapy. The ability to offer this type of comprehensive care was a likely contributor to the 
success of the program.  
Scientifically, it is difficult to determine why this treatment program is such a 
success. Perhaps regular health professional contact, accountability, and oversight of the 
patients played a key role in the outcome. In two recent Cochrane reviews of pelvic floor 
muscle training for the treatment of urinary incontinence, a pattern emerged in which 
women receiving more health professional contact were more likely to report improvement 
compared to women doing pelvic floor muscle training with little or no supervision 
(Herderschee et al. 2011; Hosker et al., 2007). It is unclear whether this improvement is 
related to the facilitation of patient compliance with various therapeutic modalities, placebo 
effect from the perception of higher quality care, or a desire of patients to please their 
caregivers by reporting symptom improvement. Regardless of the mechanism, patient 
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satisfaction scores reported for this service through a national patient satisfaction survey 
(Press-Ganey) were consistently the highest in this university healthcare system, often 
approaching 97%. 
It is important to give each patient a clear expectation regarding potential outcome 
of comprehensive pelvic floor rehabilitation. Taking into consideration their main 
complaints, physical examination findings, medical history, cognitive ability, and even 
financial and transportation options to achieve the best outcome. The APRNs counseled 
every patient at the initial session regarding expected outcomes. They addressed 
comorbidities and their effect on success such as morbid obesity, diabetes, smoking, older 
than 75 years, and prior treatment failure. Those with symptoms of urinary incontinence 
and minimal comorbidities were told they had a chance of achieving at least 80% 
improvement with an average of five treatments if they are compliant with exercises and 
behavior modification. Those with diagnosis of fecal incontinence and pelvic pain were 
informed they may require up to eight treatments and possible use of a battery-operated 
EGS device to perform the treatments at home after their fifth treatment. Data was not 
collected regarding the compliance of home therapy but it is worth noting that those 
subjects who were performing EGS therapy at home were less likely to perform daily 
pelvic floor exercises and recommended behavior modification.  
Accurate billing and coding information is necessary to assure success when 
incorporating comprehensive pelvic floor rehabilitation into clinical practice. The 
companies that manufacture the equipment are often adept at providing this information. 
Medicare reimbursement differs across the country and will often cover the treatments if 
the patient has a diagnosis of urinary or fecal incontinence. It is also prudent to include a 
 
 
80 
 
diagnostic code of pelvic muscle weakness or pelvic muscle spasm. Some insurers have a 
cap on the number of physical therapy sessions they will cover; those who had undergone 
physical therapy before or after comprehensive pelvic floor rehabilitation did not report a 
problem with reimbursement for treatments within the same year. The billing codes used 
do not negate coverage for treatment with a licensed physical therapist. Many clinics set 
up a system of prior authorization for treatment to determine patient out-of pocket expense. 
Patients with limited financial resources can be given the option of home EGS therapy and 
follow up every 4 weeks until they have completed 10 to 12 weeks of treatment. To date, 
Medicare reimbursement for biofeedback and EGS can differ according to region. These 
findings will add to the paucity of literature regarding the benefits and cost effectiveness 
of this comprehensive therapy.  Hopefully other researchers will step up and reproduce 
these findings which could ultimately motivate Medicare and private health insurers to 
offer consistent reimbursement for the treatment.  
These study findings detailing the comprehensive nonsurgical management of PFD 
in women are the first to scientifically measure QOL outcomes at end treatment and for up 
to one year. Data collection for six and twelve month post treatment is ongoing for those 
subjects that completed treatment within the past 12 months. The data base will allow for 
future analysis on areas such as demographics to reveal which patients are most likely to 
benefit from treatment and which are more likely to be compliant with behavior 
modification and completion of treatment. Analysis of the EMG and anal manometry data 
may reveal insight into changes in pelvic muscle strengthening and specific EGS 
frequencies most likely to benefit certain diagnoses.  
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                            Future Research     
Ongoing research in the nonsurgical management of women with symptoms of 
PFD is necessary to advance the science in this field. The next step is to increase the level 
of evidence by breaking down the individual treatment modalities and design trials to 
include control groups. A recent Cochrane review of the efficacy of EGS in the treatment 
of urinary incontinence concluded that EGS shows promise in treating OAB, compared to 
no active treatment, placebo/sham treatment, pelvic floor muscle training and drug 
treatment. The authors stated that adding EGS to other treatments such as pelvic floor 
muscle training may be beneficial however, the quality of evidence is low and more 
adequately powered studies should be carried out measuring subjective outcomes and 
adverse effects (Stewart et al 2016).  
The results of the secondary analysis revealed positive long term outcomes in 
symptom control following treatment, however it did not analyze or measure QOL on 
specific types of urinary incontinence. Future research is needed comparing women with 
stress, urge or mixed incontinence who undergo vaginal EGS vs sham treatment alone. 
There is an effort currently underway with the manufacturer of the EGS equipment to 
design a sham device and begin safety testing. Research questions of interest include “what 
is the difference between women with symptoms of overactive bladder who undergo EGS 
therapy compared to women with symptoms of overactive bladder who undergo EGS sham 
treatment?” Another understudied area is the use of specific frequencies for vaginal EGS 
therapy. The manufacturers of the equipment provide guidelines, none of which are based 
on high levels of scientific evidence. The goal is to develop specific treatment guidelines 
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so that these programs can be easily incorporated into a medical outpatient setting, 
increasing access to care for women with symptoms of PFD.  
Women with symptoms of PFD should have easy access to programs designed to 
comprehensively treat this sometimes complex presentation of symptoms. Specific 
treatment guidelines are being developed so that this type of program can be easily and 
affordably incorporated into a medical outpatient setting. The more evidence that can be 
collected and published can potentially increase the number of providers who are willing 
to set up this type of program in their clinic increasing affordable access to care for women 
with symptoms of PFD.  
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Appendix A.  Pelvic Floor Dysfunction Index-20 (PFDI-20) 
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Appendix B.  Pelvic Floor Impact Questionnaire-7 (PFIQ-7) 
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Appendix C.  Pelvic Floor Therapy Evaluation Form 
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